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ABSTRACT 
 
Cancer is a disease that affects millions of people each year and it is well established 
that early diagnosis is a key factor towards improving survival rate, with that in mind 
there is a great need for better diagnostics. From the earliest onset of cancer, changes can 
be detected in the type and amount of carbohydrates expressed by the cancer cells, i.e., 
aberrant glycosylation.  This process results in differing glycosylation patterns that can be 
used to detect cancer. Aberrant glycosylation can also greatly affect the potential of 
cancer cells to metastasize and can be used to stage the disease as well. In order to study 
these unique glycosylation patterns, synthetic lectins have been developed that are used 
in a cross-reactive sensor array. This array has not only been shown to be able to 
differentiate several cancer cell lines among different types of cancer, but also by 
metastatic potential. 
Specifically, the dissertation will describe 1) investigating the assay’s effectiveness 
with secreted proteins, rather than membrane proteins, to develop a fluid-based 
diagnostic, 2) the investigation of the metastatic reversion of an isogenic cell line, 3) the 
use of the synthetic lectin array to diagnose colon cancer in a longitudinal mouse study, 
and 4) the application of statistical methods to the sensor array data to draw biochemical 
information.
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: CHAPTER 1
INTRODUCTION AND BACKGROUND 
1.0 ABSTRACT 
Colon cancer is the third leading cause of cancer for both men and women.  Early 
diagnosis is essential for optimal patient outcome.  This chapter will discuss current colon 
cancer diagnostics and the necessity for a new colon cancer diagnostic.  It will also 
discuss the Lavigne group’s approach to investigating aberrant glycosylation as it relates 
to cancer development and progression as a possible diagnostic target.   
1.1 COLORECTAL CANCER FACTS AND CURRENT DIAGNOSTICS 
In 2008, 7.6 million deaths worldwide were attributed to cancer, accounting for 1 
in every 4 deaths in the United States.  For both men and women, colorectal cancer is the 
3rd deadliest in the United States.1 In 2015, it was estimated that approximately 50,000 
deaths would be due to colorectal cancer.2  
With the number of deaths attributed to colorectal cancer, early detection of 
colorectal cancer is essential for improved patient outcome.  If this disease is diagnosed 
before metastasis the five-year survival rates are reported to be around 90%, however, if 
diagnosed after metastasis the five-year survival rates are only around 12%.3 Current 
diagnostics for colon cancer are invasive and lack accuracy especially in the early stages 
of cancer. 
The most common diagnostic for colon cancer is a colonoscopy, which allows 
visualization of the colon and removal of tissue (polyps) for diagnosis and staging.  There 
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can be many risk factors associated with this procedure, including but not limited to, 
bleeding, inflammation of the abdominal cavity, and in some cases, perforation of the 
intestinal wall.4 Studies suggest that the efficacy of the colonoscopy depends upon the 
site of the cancer or neoplasm.5-6 One particular study followed approximately 55,000 
individuals who had received a colonoscopy and found that receiving a colonoscopy 
reduced colorectal cancer mortality by 29%.  When diagnosing distal colorectal cancer 
there was a 47% reduction in mortality, however, there was no reduction in mortality 
when it had to do with proximal colorectal cancer.6 
There are a couple of newer (within the last decade) diagnostics that screen for 
colon cancer by looking for hidden blood in the stool.  These tests include the fecal 
immunochemical test (FIT) and the guaiac-based fecal occult blood test (gFOBT). The 
drawback with both diagnostics is that they can diagnose cancer, but cannot identify 
neoplasms.  Unless a tumor is actively bleeding this test will show a negative result, thus 
requiring that multiple tests be performed.  Studies demonstrated that the FIT, previously 
known as immunochemical fecal occult blood testing (iFOBT), is a superior test in 
diagnosing cancer relative to the gFOBT.7-9 If either of these diagnostics find a positive 
result, the patient is then scheduled for a colonoscopy, which has its own disadvantages 
that were discussed previously.10 While the FIT has success with identifying advances 
neoplasms, the main disadvantage with the FIT is that it has higher false-negative results 
in detecting T1 cancer versus T2-T4.11  
In comparing both the fecal immunochemical test and a colonoscopy, there a few 
factors to consider: diagnostic usefulness, accessibility to underserved patients, and 
favorability of the screening technique.  With the above information it can be seen that a 
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colonoscopy is a better diagnostic tool than the fecal immunochemical test (FIT).12 In 
terms of accessibility to underserved patients, the FIT is a less expensive test than a 
colonoscopy, which is particularly important to the uninsured.  Uninsured people have 
screening rates of 20.7% compared with people who have private insurance having 
screen rates of 65%.13 In 2012, it was reported that in the United States 48 million people 
do not have health insurance. With data suggesting that the cost for health care for cancer 
in the United States in 2011 was $88.7 billion dollars, the cost of these screening methods 
needs to be considered.2 Studies also show that patients, whether insured or uninsured, 
are more inclined to participate in screening when the FIT is suggested rather than a 
colonoscopy.13-14   
There are other less-used diagnostics that utilize biomarkers to diagnose and stage 
colorectal cancer.  Carcinoembryonic antigen (CEA) is a glycosylated cell-surface 
glycoprotein.  In healthy patients, CEA levels can range from 2.5 to 5 ng/mL.  Testing of 
CEA levels in patients with colorectal cancer indicated that 4% of patients with stage I 
cancer had elevated levels of CEA, while 25 % of patients with stage II cancer had 
elevated levels.15 In 2000, the American Society of Clinical Oncology (ASCO) 
recommended that the CEA test no longer be used as a diagnostic tool, but rather be used 
to monitor disease progression if no other test was available.  The ASCO also 
recommended that CA 19-9, another biomarker often used to diagnose colon cancer, not 
be used to diagnose or to monitor the disease.16  
With the given information about current colon cancer diagnostics it is clear that a 
novel colon cancer diagnostic is necessary.  Ideally, this would be inexpensive in order to 
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be a feasible option for those in a low socioeconomic class and for those uninsured.  It 
would be best if this had high accuracy with low risk and limited test preparation. 
1.2 ABERRANT GLYCOSYLATION 
Glycosylation is a post-translational modification where a carbohydrate chain is 
attached to a membrane or secretory protein.  There are two major types of 
oligosaccharides found on glycoproteins–N-linked and O-linked.  O-linked are 
oligosaccharides are linked to a serine or threonine residue while N-linked are linked to 
the amide nitrogen of an asparagine residue.17 
Aberrant glycosylation is known to take place at the onset of many diseases 
including cancer as well as inflammation.  The glycans present on the glycoproteins can 
be under, over, or neo-expressed.  It is important to note that aberrant glycosylation 
occurs on both the membrane-bound proteins as well as the secretory proteins.18 This 
process takes place at the onset of cancer and continues as the disease progresses.19 
Aberrant glycosylation can lead to an increased amount of N-branching in malignant cells 
leading to more sialyl lewis x (sLex) residues.  There is also a correlation with increased 
N-branching and increased metastatic potential. More will be discussed surrounding sLex 
in the Section 1.3.20   
1.3 CANCER ASSOCIATED GLYANS 
The previous section mentioned the importance of glycosylation in terms of 
understanding cancer and cancer progression.  Cancer associated glycans (CAGs), 
sometimes referred to as tumor associated carbohydrate antigens (TACAs), are glycans 
that have been shown to be of particular importance to different areas of cancer, i.e. 
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disease progression, proliferation, metastasis, etc.  The structures of common cancer 
associated glycans are shown below in Figure 1.1.   
 
Figure 1.1: Structures of common cancer associated glycans. 
One cancer-associated glycan, sialyl lewis x, a tetra-saccharide, has been 
theorized to be involved in metastasis, the cancer spreading from the primary tumor to 
other areas in the body.  It is thought that the sLex present on the surface of the cell is 
able to bind with a lectin (E/P selectin) in order to begin the process of intravasation, 
where the a cancerous cell makes its way into the vasculature, as well as extravasation, 
where the cancerous cell makes its way out of the vasculature at a secondary tumor site.  
Selectins, a class of lectins, are cell adhesion molecules that bind glycans.  Selectins play 
a role in the intravasation of cancer cells in order for these cells to migrate to secondary 
tumor sites.21 
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A large review of the role of glycans in cancer reported that it is not one particular 
change in a glycan that happens in cancer, but rather a pattern of glycan changes. Table 
1.1 indicates that over-expression of cancer-associated glycans for different cancer types. 
Table 1.1: Overexpression of cancer associated glycans by tissue type.18 
 
It is interesting to note, that each cancer type has its unique pattern, however, 
some cancer types display similar patterns.  For instance, breast cancer and colon cancer 
have very similar patterns, except breast cancer has the over-expression of polysialic acid 
(PSA), while colon cancer does not.22 An ideal diagnostic would be one that would be 
able to detect changes in glycosylation.   
1.4 NATURAL LECTINS USED IN CANCER DIAGNOSTICS 
Lectins are carbohydrate-binding proteins that serve a variety of functions in the 
body.  Lectins can serve as recognition signals on the surface of the cell23, play a role in 
protein folding and cell-cell interaction24.  They can also be involved in cellular functions 
like endocytosis, cell adhesion, cell migration, and transport. Their interactions with 
carbohydrates are generally reversible in nature.25 A common example of a viral protein 
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that binds to carbohydrates is influenza hemagglutinin.  This protein has sites that bind to 
sialic acid present on a cell surface to initiate the interaction of the virus and host cell.24   
With lectins having high selectivity for a particular target, natural lectins and 
natural lectin arrays have been of interest in research in a variety of areas, however, we 
will limit this discussion to cancer-related areas.  Researchers are investigating lectins as 
possible diagnostic and therapeutic tools.26-27 
  One such study investigated natural lectin microarrays as a means for 
distinguishing glycosylation patterns in serum from normal patients and patients with 
pancreatic cancer.  This study used five different lectins, however, due to the specificity 
of lectins only seven different glycan structures could be detected.  The researchers were 
able to distinguish between serum samples; however, the experiments required a large 
amount of sample preparation.  It also only probed a small amount of glycosylation 
changes that could occur from patient to patient.26 
Another study investigated the glycan profile from healthy patients, patients with 
colon adenomas, and those with colorectal cancer in order to determine a potential colon 
cancer biomarker.  This study also used five different natural lectins, which as discussed 
previously only probes a limited amount of glycan structures.  The study concluded that 
while using some natural lectins, patients with colon cancer, adenomas, and no 
cancer/adenomas could be successfully separated.  However, there were some natural 
lectins that did not provide this type of information.  They also discussed that the patients 
with cancer had an increased level of sialylation and fucosylation27, however another 
study mentioned that sialylation could be increased up to a two-fold difference from 
patient to patient.26 
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While natural lectins can prove to be valuable for gaining information about 
glycosylation patterns, there are a few disadvantages to using them.  They are very 
specific for a particular sugar and or sugar linkage, which can be good in some cases. 
However, it is known that a glycan profile can change depending on cancer type.  If there 
is no known lectin to probe this change, the efficacy of the lectin in a diagnostic reduces.  
The natural lectins can be particularly difficult to work with and many of the studies that 
are utilizing these lectins require a large amount of sample preparation and purification. 
There is not one particular glycan change that can differentiate diseased tissue from 
normal tissue.  This would indicate that it would be advantageous to look for a way of 
detecting glycan changes that are not as specific as natural lectins.  The above reasons are 
why the research groups have chosen to create synthetic lectins28-30, which will be talked 
about in further detail in subsequent sections of this chapter. 
1.5 BORONIC ACID-DIOL INTERACTION 
To investigate the changes in glycosylation and design a sensor to monitor these 
changes, a part of the sensor has to interact with the glycans.  In looking at some of the 
structures in Figure 1.1, it can be seen that all of the structures contain diols.  Boronic 
acids have the ability to bind 1, 2 and 1, 3-diols covalently, with high affinity, yet 
reversibly to form 5- or 6-membered boronate esters.31-34 This interaction is generally 
stronger with cis-diols than trans-diols.35  Figure 1.2 depicts the formation of this 
boronate ester from a boronic acid binding covalently with a 1,2 and 1,3 diol. 
 9 
 
Figure 1.2: Interaction of boronic acid with 1,2 and 1,3 diols to form a boronate ester 
The reversibility of this interaction is what makes boronic acids useful in a saccharide 
sensor.  The boronic acid is capable of binding strongly to a carbohydrate, however, if a 
different carbohydrate has a stronger interaction the first will unbind and the second will 
bind.  This property would ensure that the sensor would bind with whichever saccharides 
had the strongest interaction. 
1.6 BORONIC ACID SENSORS FOR SACCHARIDES 
With the strong, yet reversible, interaction boronic acids are capable of making 
with 1,2 and 1,3 diols, boronic acids have been used as part of a sensor for saccharides.36-
39 This research has been applicable to cancer research as well as other diseases, such as, 
diabetes.   
Sialyl lewis X has been associated with metastasis as well as part of the glycan 
pattern seen in different cancer types.  Some research has been used to find a fluorescent 
di-boronic acid sensor that can correctly identify those cells containing sLex, while also 
having a negative interaction with those cells that do not have sLex.38-39  
While the above examples used boronic acid sensors for applications in cancer, 
they have also been studied for use as a non-invasive glucose sensor for patients with 
diabetes.34-35 Boronic acid sensors have also been used as a way to study non-covalent 
drug delivery.40 
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1.7 CROSS-REACTIVE SENSOR ARRAYS  
The previous applications with natural lectins involve the lectins binding with 
high affinity with the glycans specific for lectin. This interaction is similar to an 
antigen/antibody interaction.  In looking at these applications as well as the biomarkers 
discussed in the colon cancer diagnostics section, looking for one biomarker that has a 
high affinity may not be the best approach.  Rather than thinking about one sensor for one 
analyte, one can think about a set of cross-reactive sensors forming a sensor array. This 
type of interaction is depicted in Figure 1.3.41 
 
Figure 1.3: This figure depicts the interaction of nine different sensors with a single analyte to produce a unique 
pattern.41 
With this approach, one analyte (the red oval) has an interaction with a series of sensors.  
This interaction can then produce a unique pattern depending on the interaction (or lack 
of) and the strength of the interaction.   Therefore, the response is the entire pattern.  This 
is similar to the mammalian sense of taste or smell.  There is not a receptor for each type 
of food, but rather the response of 4 taste buds (sensors) that send a signal to your brain 
to recognize what is being eaten.   
1.8 SYNTHETIC LECTINS 
In order to mimic the interactions between natural lectins and glycans while 
avoiding the disadvantages of using natural lectins, the Lavigne lab developed synthetic 
Differential Receptors Single Analyte Pattern 
Lavigne, Anslyn Angew. Chem. Int. Ed. 2001, 3118 17	
read	
out	
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lectins.  These synthetic lectins were short peptide chains functionalized with boronic 
acids attached to a resin.  The advantages to using synthetic lectins are that they are easy 
to synthesize, biocompatible, and have low toxicity. 
 
Figure 1.4: Schematic of a generalized synthetic lectin attached to a resin bead. 
Figure 1.4 depicts a general synthetic lectin on a resin.  It depicts one synthetic lectin on a 
bead, however it reality there are many more than one.  The M, R, and B represent the 
one-letter amino acid codes with B standing for β-alanine.  The X represents a random 
amino acid chosen.  The boronic acids are attached to a non-natural amino acid, 
diaminobutyric acid, represented as Dab in Figure 1.4.   
 
Figure 1.5: Boronic acid and SL interaction with a glycan or glycoprotein. 
The attached boronic acids would interact with 1,2 and 1,3-diols present on sugar 
residues forming a boronate ester. This interaction is depicted in Figure 1.5.42  
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1.9 FINDING SYNTHETIC LECTINS 
In order to find the synthetic lectins to use, a library was made using a split and 
pool method depicted in Figure 1.6a.  A portion of the resin was split into individual 
tubes and a single amino acid was attached, a different amino acid for each tube.  The 
resin was pooled into a tube and re-split so that another amino acid could be added.  After 
all of the random amino acids were added and then end of the peptide was acylated, 
boronic acids were attached.  Theoretically the synthetic lectin, and more specifically the 
boronic acids would interact with 1,2 and 1,3-diols. 
 
Figure 1.6: a) Split and pool method of creating a library. b) Identifying hit and sequencing of the library. 
In order to find SLs that would interact with carbohydrate structures, the library 
was incubated with fluorescently labeled purified glycoproteins, Ovalbumin (OVA), 
porcine stomach mucin (PSM), and bovine sub-maxillary mucin (BSM).  Figure 1.6b 
depicts this process.  The purified glycoproteins were of varying carbohydrate 
composition.  After incubation, the excess FITC was washed away and hits were 
identified using fluorescence microscopy.  A “hit” was determined to be a bead that 
fluoresced more than the others beads.  The fluorescing of the bead would indicate an 
interaction between the synthetic lectin and the glycoprotein.  The hits were manually 
Split
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removed from the other beads and the bead sequenced by MS/MS.  The sequences for SL 
1, 3, 4, and 5 are shown in Table 1.2. 
Table 1.2: Sequences for SLs 1, 3, 4, and 5 
 
  The research involved in Chapter 2 and 3 discuss the use of SLs 1-9, however, 
the following research presented in Chapter 1 will only discuss the use of SLs 1, 3, 4, and 
5.  It was not until after this research was published, that an expanded SL array was 
investigated.  The sequences for the remaining SLs are listed in Table 2.1.   
1.10 SYNTHETIC LECTINS INCUBATED CANCER ASSOCIATED GLYCANS 
Following the hits being sequenced, the SLs were re-synthesized.  There were a 
variety of experiments done in order to optimize the use of the SLs, however, only ones 
pertinent to this dissertation will be discussed.  The re-synthesized SLs were incubated 
with fluorescently labeled cancer associated glycans. 
 
Figure 1.7: SLs 1, 3, 4, and 5 interaction with cancer associated glycans 
SL	ID Sequence Selec,vity 
SL	1 Ac-RGD*VTFD*RBBRM OVA 
SL	3 Ac-RSD*VTTD*RBBRM PSM 
SL	4 Ac-RRD*TQTD*QBBRM OVA	and	PSM 
SL	5 Ac-RAD*TRVD*VBBRM PSM 
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Figure 1.7 depicts the interaction that each SL had with each cancer associated 
glycan.  It is important to note that each SL was incubated with each CAG separately.  
The y-axis is the normalized average luminosity.  These values were found by manually 
circling each bead in Adobe Photoshop®.  Essentially, the stronger boronic acid-diol 
interaction is the larger the normalized average luminosity value. 
The important part about the interactions shown above is that each cancer- 
associated glycan has a unique fingerprint pattern that the four SLs create.  For instance, 
if one looks at the response of SL1 with Lex and sLex it may be difficult, taking into 
account the error bars, to distinguish one from another.  However, if this response is 
expanded to looking at the SL 1 and SL 3 response, it starts to become more clear that 
these are different.   
It is challenging to look at a bar graph to decipher which responses are different, 
which is why a statistical method called linear discriminant analysis (LDA) is used.  This 
method attempts to reduce the dimensionality of the data into two dimensions.  When 
reducing the dimensionality, the statistical model attempts to minimize the separation 
within the same group, while maximizing the differences between other groups.  The 
important thing to note about LDA is that it is a guided statistical method, meaning that 
the computer program is given information about which group each data point should 
belong.  Figure 1.8 is the LDA plot generated from the data in Figure 1.7. 
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Figure 1.8: LDA plot generated with response from SL 1, 3, 4, and 5 with cancer associated glycans. 
Each shape in Figure 1.8 represents the array’s response from four different 
synthetic lectins.  Recall that the program is attempting to group all of the sLex points 
(black triangles) as close together as possible, while attempting to group these points 
away from the Lex data points (green triangles).  The circles surrounding the data points 
represent the 95% confidence intervals.  LDA is capable of giving cross-validation values 
meaning that it will take a point out, for example a black triangle, and the program will 
attempt to put that black triangle back in and see where that point will classify itself.  
This particular data set has a classification accuracy of 97%.  The interesting thing to note 
is that while there is some overlapping above, for instance between Lea (red squares) and 
sLea (pink triangles), these sugars are structurally similar.  The only difference between 
these two polysaccharides is the addition of a sialic acid group in the sLea 
polysaccharide.42   
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1.11 SYNTHETIC LECTINS WITH CELL LINES 
Being that the SL array response was able to discriminate between structurally 
similar polysaccharides, the next step was to determine if the SLs were able to distinguish 
differing cell lines of varying metastatic potential.  Metastatic potential will be used 
throughout the duration of this dissertation and refers to whether the cell line is 
considered healthy/normal, cancerous non-metastatic/lowly-metastatic, and cancerous 
metastatic.  Table 1.3 lists the cell lines used in the experiment described.  For each cell 
line the table lists the metastatic potential, cancer type (if applicable), and the origin of 
the cancer cell line if it was metastatic, and the species this cancer is derived from.  For 
instance, LoVo is a human colon cancer metastatic cell line.  While it is a colon cancer 
cell line, it was obtained from its secondary site, a lymph node.  CT26-F1 and CT26-FL3 
have an asterisk next to them denoting that these are isogenic cell lines meaning that they 
are derived from the same parent cell line, CT26.  For clarity, CT26 is considered non-
metastatic/lowly metastatic.  No cell line can be completely non-metastatic because given 
the right conditions a cell can migrate, however, if a cell line has a very low metastatic 
potential rate it is usually considered non-metastatic. CT26 has a very low metastatic 
potential (0-5%) and thus is considered non-metastatic.  CT26-F1 is cancerous metastatic 
with a metastatic rate of 50%, and CT26-FL3 is highly metastatic with a metastatic rate 
of 95%.  
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Table 1.3: Cell lines used to evaluate SL array response with cell lines. 
 
The cell lines were grown according to ATCC guidelines and the membrane 
proteins/glycoproteins were extracted using the Qiagen® membrane extraction kit.  
Proteins were labeled with FITC and incubated with the four SLs.  The beads were 
analyzed using fluorescence microscopy and imaged.  The bright values were obtained 
using Adobe Photoshop® as described earlier in this chapter.  The fingerprint pattern was 
obtained and LDA was used to better distinguish the similarities and differences in the 
array response, similarly to how LDA was used while analyzing the SL array with cancer 
associated glycans described previously.  Figure 1.9 illustrates the LDA plot obtained 
from the SL array’s response with each cell line. Each point is the individual response 
from each of the four SLs with that particular cell line.    
 
Cell	Line	 Classiﬁca,on	 Cancer	Type	 Origin	 Species	
3T3/NIH	 Healthy		 N/A	 Mouse	
CT-26	 Cancerous,	Non-Metasta;c	 Colon	 Mouse	
HCT116	 Cancerous,	Non-Metasta;c	 Colon	 Human	
HT29	 Cancerous,	Non-Metasta;c	 Colon	 Human	
Lovo	 Metasta;c		 Colon	 Lymph	Node	 Human	
*CT26-F1	 Metasta;c		 Colon	 Liver	 Mouse	
*CT26-FL3	 Metasta;c		 Colon	 Liver	 	Mouse	
*		Denotes	the	cell	line	is	isogenic	
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Figure 1.9: SL array response with cell lines of varying metastatic potential. a) illustrates classification based on 
individual cell line while b) illustrates classification based on metastatic potential.42 
In Figure 1.9a, the data was grouped/classified based on cell line.  For example, 
the program knew that each 3T3 point (black diamond) was different than each HT29 
point (orange circle).  The program had a cross-validation of 92% when classified by cell 
line.  However when thinking about a clinically relevant diagnostic, at first pass it is more 
important to answer the following questions: Do I have cancer? and Has the cancer 
metastasized? than to know if one has HCT 116 vs. HT29.  Figure 1.9b takes these 
questions into account.  In this LDA plot, the data is grouped by metastatic potential 
(healthy, cancerous non-metastatic, and cancerous metastatic.  When classified by 
metastatic potential, the cross-validation accuracy is 97%.  The false-negative and false-
positive rates were found by manually going through the output and looking at whether a 
cancerous data point was misclassified as healthy or a healthy point was misclassified as 
cancerous respectively.42 
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1.12 DATA PROCESSING 
The data analyzed in this chapter was analyzed differently than what will be 
discussed in the rest of the dissertation.  The previous luminosity data for the interaction 
between the SL and carbohydrates was found by incubating the SL with fluorescently 
labeled glycoprotein and imaging with a fluorescence microscope.  After imaging, in 
order to obtain fluorescence intensity information, Adobe Photoshop® was used.  Within 
this program, a bead was isolated and a histogram generated to give a “bright value”.  
The work presented in Chapters 2-4 will use a slightly varied experimental set-up.  Figure 
1.10 depicts the workflow used. 
 
Figure 1.10: Experimental workflow used for the data presented in the following chapters. 
 The synthetic lectins on beads were incubated with fluorescently labeled 
glycoproteins and these beads were imaged in the same was as discussed previously in 
this chapter.  A typical image is shown in the figure above.  The image was run through a 
program in MATLAB® rather than using Adobe Photoshop.   
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The program used was one written by Dr. Andrew Greytak, University of South 
Carolina Chemistry Department.  As can be seen from the figure, there is a white box in 
the middle of the photo.  This is called the Region of Interest (ROI) and was used in the 
MATLAB® program.  Only beads inside this region (not touching the border) are 
analyzed.  This was used because it was noted that beads directly under the light source 
fluoresce brighter than those on the outside of the ROI.  The beads may not have 
necessarily been different intensities, but the difference may have been due to how much 
of the light source was over the bead. 
The program gives a variety of information about the bead.  It gives information 
about bead size, circularity, area, and luminosity information.  The luminosity 
information is given in three channels (red, green, and blue) as well as a “bright” number, 
which is a weighted average of the first three with the green number being a much larger 
factor than the red or blue.  The green number would be the largest value for these 
experiments because the bead is incubated with FITC labeled glycoproteins and imaged 
under a GFP filter.  In order for a bead to be counted as “valid” it needs to have an 
appropriate area to ensure that the program is not counting two beads as one.  The bead 
must be circular to avoid the program looking at bead fragments. 
Due to the bit size of the camera, the maximum value for bead intensity is 255.  
Therefore, in order to obtain information for each bead, the intensity value must be 
between 0 and 255.  To optimize the exposure time and be sure that no synthetic lectin is 
too bright or dim, each synthetic lectin used (SL 1-9) with a particular analyte is placed 
under the camera.  The brightest SL is found and the time is optimized in order to make 
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sure that with the exposure time picked the bright number is not above 255.  Each SL is 
then imaged at the optimized exposure time. 
Following imaging and data extraction from the MATLAB® program, the data is 
processed using Excel®.  The sensor array data will be referred to as either normalized or 
raw.  If the data is raw, the bright or green numbers used will be the numbers given 
directly from the MATLAB® program, therefore all of the data was on a scale from 0-
255, the scale of the camera.  Being that each analyte will have a different amount of 
FITC present, it was thought that normalizing the data may also be beneficial.  Therefore, 
within each individual analyte (usually a cell line) the brightest SL was found.  For 
instance, SL 1 was the brightest.  If this were the case all other SLs data points would be 
divided by SL1 to put the data on a scale from 0 to 1.  Throughout the paper, it will be 
discussed which type of data analysis was used for the sets of data. 
1.13 CONCLUSIONS 
Colorectal cancer is a disease that directly affects thousands of men and women, 
however with an early diagnosis the mortality rate decreases dramatically. Current colon 
cancer diagnostics are expensive, unreliable, and have the possibility of serious 
complications that make a novel diagnostic necessary.   
Aberrant glycosylation-the under, over, and neo expression of glycans is a process 
that occurs at the onset of cancer and progress throughout the disease both on membrane 
bound proteins and secreted proteins.   This process provides a target for a novel cancer 
diagnostic, however, the diagnostic would require something that can probe 
carbohydrates.  Synthetic lectins functionalized with boronic acids can mimic natural 
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lectins without the disadvantages to natural lectins.  The boronic acids can form covalent, 
yet reversible, bonds with 1, 2 and 1, 3 diols present on the surface of sugar moieties. 
A synthetic lectin library was created in order to find synthetic lectins, both selective 
and cross-reactive, to be used in a sensor array.  This sensor array was used to investigate 
its utility in diagnosing several different cell lines of varying metastatic potential.  The 
array was successful in classifying these cell lines by metastatic potential.  The 
subsequent chapters in this dissertation will discuss the applications of this array 
including the possibility of the array being used as a fluid-based diagnostic.  It will also 
discuss using the array to investigate metastatic potential in an isogenic cell line as well 
as a in a longitudinal mouse study. 
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: CHAPTER 2
GLYCAN DETECTION USING SECRETED PROTEIN  
2.0 ABSTRACT 
Aberrant glycosylation begins at the onset of cancer and continues throughout the 
progression of the disease.  A synthetic lectin array was developed to investigate 
glycosylation changes. The sensor array was effective in discriminating cell lines based 
on metastatic potential (healthy, cancerous non-metastatic (lowly metastatic), and 
cancerous metastatic (highly metastatic)). However, the proteins and glycoproteins used 
were membrane-bound and as a clinical diagnostic would require a biopsy for which 
there are a variety of associated disadvantages.  Ideally, a fluid-based diagnostic would 
be used.   
This chapter will discuss the need for a fluid-based diagnostic, a pre-study to 
optimize experimental conditions, and the use of secreted proteins from four human 
colon cell lines as a proof-of concept experiment to investigate the synthetic lectin array 
to be used as a fluid-based assay.  The analysis of the synthetic lectin array is able to 
discriminate membrane bound proteins of four different human colon cell lines with a 
classification accuracy of 97% and could discriminate secreted proteins from four human 
colon cell lines with a classification accuracy of 88%. This indicates that the synthetic 
lectin array was able to classify secreted proteins based on metastatic potential.  The 
chapter will also discuss the future directions for this project. 
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2.1 INTRODUCTION 
Colon cancer is the third most common type of cancer in both men and women 
worldwide with at least 600,000 colon cancer-related deaths annually.1-2 Current colon 
cancer diagnostics, e.g. colonoscopy, are invasive and often inaccurate because they rely 
on visual inspection, which can be subjective.  Monitoring cancer biomarkers using a 
fluid-based diagnostic, often referred to as a liquid biopsy, is an optimal strategy though 
existing methods suffer greatly from low effectiveness associated with high false 
negative and false positive rates. The work in this chapter describes progress towards 
developing a blood-based colon cancer diagnostic.15-16 
As previously mentioned, the approach used focuses on monitoring aberrant 
glycosylation, which impacts integral cell membrane and secreted glycoproteins from the 
onset and throughout progression of the disease.18-19 Here, boronic acid functionalized 
peptides, termed Synthetic Lectins (SLs), are used in a cross-reactive sensor array to 
monitor changes in glycosylation patterns displayed on cancer cells as well as proteins 
secreted into media/blood. 
2.2 NEED FOR FLUID BASED DIAGNOSTIC 
Current colon cancer diagnostics have serious disadvantages including reliability, 
cost, and time for results.4-13 With these factors in consideration a fluid-based diagnostic 
is ideal.  The fluids that can be considered for this type of diagnostic would include 
blood, semen, urine, etc.  A fluid-based diagnostic would reduce the cost, which is 
advantageous to uninsured populations.  It would also allow for easier sample collection.  
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2.3 BACKGROUND  
The synthetic lectin array had been investigated to determine its discriminatory 
power in differentiating between healthy, cancerous non-metastatic (lowly metastatic), 
and cancerous metastatic (highly metastatic) cell lines.  These cell lines were of different 
species with some being from mice and some from human.  The synthetic lectin array 
was effective at discriminating seven colon cell lines with a leave one out classification 
accuracy of 97%. The analysis was run with a three-class classification which means the 
seven cell lines were classified into three groups (healthy/normal, cancerous non-
metastatic, and cancerous metastatic).   
In terms of a clinical diagnostic, obtaining cells includes many of the same risk 
factors and disadvantages as current diagnostics, discussed in Chapter 1.  The following 
chapter will describe a pre-study used to optimize the conditions to grow cells and obtain 
secreted proteins as well as a proof-of-concept experiment with four human colon cell 
lines or varying metastatic potential. 
2.4 SECRETED PROTEIN PRE-STUDY 
A fluid-based diagnostic requires secreted proteins.  The SL array, up until this 
point, had investigated the array’s response with membrane bound proteins and 
glycoproteins that were extracted from cultured cells.  In order to investigate whether the 
SL array would work with secreted proteins, a proof-of-concept experiment was created 
in which the proteins secreted into media from cultured cells would be used. The primary 
questions to be answered were: Can secreted proteins be used? and What growth 
conditions would be best for this experiment?   
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Cell culture conditions usually include some sort of base media, fetal bovine 
serum (FBS), antibiotics/antimycotics, and any additives it requires.  For this first 
experiment the cell line used was CT-26 (ATCC® CRL-2638™).  This is a cancerous, 
lowly, metastatic mouse cell line.  It was chosen because it is easily grown and the 
membrane glycoproteins were used in the initial study.   
Two different growing conditions were used for this pre-study.  The +3 and +5 
seen in the paragraph below refer to the passage numbers from the cell stocks (i.e. how 
many times the cells grew confluent and were split).  Both CT26 +3 and CT26 +5 were 
grown with FBS (serum) present in the media prior to the experiment.  When the cells 
reached 70% confluence, CT26 +3 had its media (that contained FBS) replaced, while 
CT26 +5 had media without FBS (serum) added to the cells. The lack of FBS added 
means that CT26 +5 were starved for 48 hours prior to media removal. Both media 
conditions were added the cells 48 hours prior to media removal. 
Antibiotics/antimycotics were present in both cell culture scenarios.  
After 48 hours the media was removed from the cells and centrifuged to remove 
cell debris.  The media was pipetted off and put in a new tube.  The media was 
centrifuged in Amicon® 3K centrifuge tubes (EMD Millipore) and the proteins were 
precipitated with cold acetone.  The acetone was then removed and the protein was put 
into carbonate buffer for fluorescent labeling.  The amount of carbonate buffer added 
changes depending on the amount of protein present.  Generally 1-2 mL was used to 
make a homogenous protein solution.  In order to quantify the protein concentration, a 
BCA assay was done.  A small amount of protein solution (200-300 µL) was taken to 
label.  It is advantageous to label a portion of the total protein if further experiments need 
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to be done.  The protein was labeled with fluorescein isothiocyanate (FITC) and the 
solvent exchanged to PBS using Amicon® 10K centrifuge tubes (EMD Millipore).  A 
BCA assay was repeated to quantify the amount of labeled protein. 
 Previously, the SL array has been used with membrane proteins/ glycoproteins 
from the seven different cells lines of varying metastatic potential as well as purified 
proteins (BSA, BSM, PSM, and OVA).  For the pre-study, the experimental workflow 
that was followed was the same workflow for the incubation of purified proteins, which 
requires a larger protein concentration (0.1mg/mL) and a longer incubation time (20 
hours) with the SLs.  This protocol was used due to the homogeneous nature of the 
secreted proteins.  Prior to incubation the beads containing the SLs were washed with 
PBS twice. The beads were incubated with PBS containing 1% BSA for 15 minutes.  
This solution was removed and 1 mL of the protein solution at the desired concentration 
was added to nine tubes, each independently containing approximately 2 mg of a 
different SL (SL 1-9).  After incubation, the beads were washed three times with PBS.  
Each tube of beads was imaged using a fluorescence microscope, Leica® MZ 16F, using a 
GFP filter set.  
Previous work used SLs 1,3,4, and 5 for the array,however, work done 
concurrently in the lab at the time of this experiment demonstrated an expanded SL array 
using SLs 1-9 had higher classification accuracies.  For this reason, the expanded array 
was used for all of the experiments presented in this chapter.  The sequences for SLs 1-9 
are shown below in Table 2.1.  The glycoprotein that each SL was found to be selective 
for is also shown.  Synthetic lectins 6-8 were found to be cross-reactive. 
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Table 2.1: SL 1-9 Sequence and Selectivity Information 
 
Figure 2.1 represents the data acquisition and processing after incubation with the SLs. 
Each tube of beads was imaged using a fluorescence microscope, Leica® MZ 16F, using a 
GFP filter set.  The images are analyzed with a MATLAB® program and process with 
Microsoft Excel®.  Following data processing, is data analysis using various statistical 
methods (i.e. LDA or PCA).   
 
Figure 2.1: Data processing and acquisition workflow. 
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Each synthetic lectin incubated with each analyte was imaged using a camera and 
fluorescent microscope.  Each synthetic lectin incubated with each analyte will give a 
fluorescent response depending upon the level of interaction.  The pictures imaged with 
the camera are run through a program in MATLAB® that was written by Dr. Andrew 
Greytak.  This allows a numerical value to be assigned for fluorescent intensity.  As 
discussed in Chapter 1, each analyte will have a unique fingerprint pattern created by all 
nine synthetic lectins.  While looking at the fingerprint patterns can be valuable it 
becomes confusing when attempting to find similarities and differences between analytes. 
For this reason, statistical methods are implemented.  For this analysis, linear 
discriminant analysis (LDA) was used.  LDA is a guided statistical method meaning that 
the statistical software knows which group each analyte (cell line) should belong.  
Because the cell lines used have well-established metastatic potentials this was the 
method chosen. 
Figure 2.2 is the linear discriminant analysis plot generated with Systat® 7 and 
plotted in Microsoft Excel®.  This plot was generated as a three-class classification, 
which means that each analyte (cell line) classifies as one of three groups.  The three 
main groups of importance are the healthy (red squares), non-metastatic (purple circles), 
and metastatic (blue diamonds) cell lines.  CT26 is a non-metastatic (lowly) cell line, 
however, for ease of data interpretation all CT26 points are plotted as a green triangle. It 
is important to note that all of the data points except for CT26 +3 and CT26 +5 were 
generated from membrane bound proteins and glycoproteins.  The data points used 
except for CT26 +3 and CT26 +5 represent the data collected by Kevin Bicker and Jing 
Sun.  
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Figure 2.2: Secreted Protein Initial Study Results.  The CT26 +3 cells (black outlined green triangles) were 
grown with FBS prior to secreted protein isolation from media, while the CT26 +5 cells (black outline pink 
triangles) were starved (no FBS) prior to secreted protein isolation from media.  It was decided that the 
approach taken would be that or starving the cells prior to secreted protein isolation from media due to the 
perceived scattering of the CT-26 +3 data points. 
The first question was whether secreted proteins worked with the SL array.  As 
seen in Figure 2.2, it is seen that a response is generated from SLs 1-9 with both CT-26 
+3 and CT-26 +5.  Both of these analytes classify well with the existing cell membrane 
data.  This was a promising sign because the secreted protein contained in the media is a 
more heterogeneous mixture of proteins than the cell membrane proteins. 
The second question had to do with what growth conditions were optimal during 
cell culture.  All of the colon cell lines use Fetal Bovine Serum (FBS) as a growth 
substitute.  The main issue with this is that albumin is a large component of FBS.  Being 
that the proteins secreted are heterogeneous, it was a concern that the albumin would 
mask proteins/glycoproteins of interest in the sample.  It was assumed that the albumin 
would be in all of the sample in a large quantity.  By removing this factor the 
glycoproteins with aberrant glycosylation could be detected.  As mentioned before, two 
passages of CT-26 were grown labeled as CT-26 +3 and CT-26 +5 in Figure 2.2.  Both 
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passages were grown to 70% confluence and new media was added to the cells for 48 
hours.  In the case of CT-26 +3 complete media was added to the flasks of cells, meaning 
that FBS was included, however for CT-26 +5 media without FBS was used.  In 
analyzing Figure 2.2, it was expected that both CT26 passages would overlap with the 
cell membrane array response and sit over the CT-26 data points (the green triangles) or 
at least over the rest of the non-metastatic data points (the purple circles).  It can be seen 
that while both overlap reasonably well, the cells that were starved (CT-26 +5) seem to 
overlap better with the previous data including less scattering.   
It was expected that the cells that were starved would have a consistent response 
with the array, as seen from the CT26 membrane bound glycoproteins. This was 
advantageous for a few reasons.  The first of which was sample workflow which will be 
talked about in Section 2.5.  Using albumin-free media significantly cut down on time in 
the sample centrifugation part of the workflow.  The second reason this was 
advantageous was because studies in blood-based proteomic techniques generally discuss 
removing the albumin as an optimal strategy for unmasking proteins of interest.43   
Albumin can tend to overwhelm the signal not allowing the SLs to detect glycosylation 
changes on the secreted proteins.  The third reason this was advantageous was the clinical 
relevance of removing the albumin.  Many diagnostics that are used clinically remove 
albumin after the blood draw as albumin is the most abundant protein in serum samples.44 
Using serum-free media would allow the SL array to more closely mimic protocols that 
are clinically relevant.  
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2.5 SECRETED PROTEIN STUDY WORKFLOW 
With the results of the pre-study in mind, a larger secreted protein study was 
developed.  In order to provide a more clinically relevant study, only human colon cell 
lines were chosen.  Four human colon cell lines of varying metastatic potential were used 
for these experiments.  CCD-841-CON (ATCC® CRL-1790™)45 was the normal or 
healthy colon cell line used.  HCT-116 (ATCC® CCL-247™)46 and HT29 (HTB-38™)47 
were the cancerous non-metastatic (lowly metastatic) cell lines used. LoVo (ATCC® 
CCL-229™)48 was the highly metastatic cell line used derived from the left 
supraclavicular region (secondary site) of a male.  All cell lines were grown according to 
ATCC® guidelines. Table 2.2 lists the cell lines used in this experiment with the 
associated metastatic classification.  If the cell line is metastatic, it also lists the origin of 
the cell line (i.e. the secondary site). 
Table 2.2: Four human colon cell lines used in this experiment with the associated metastatic classification.  
 
The pre-study used protein concentrations of 0.1 mg/mL, however, to keep this 
study consistent with the cell membrane data already collected a 50-fold dilution of a 
0.01 mg/mL solution was used for a final concentration of 0.0002 mg/mL.  The pre-study 
indicated that a 0.1 mg/mL solution would correlated with membrane bound protein, 
however, the concentration was chosen in order to stay consistent with published data.  
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The experiment designed used both membrane-bound proteins as well as secreted 
proteins.  In order to keep cellular transformation between passage numbers to a 
minimum, the membrane bound proteins would be extracted from the cells and the 
secreted proteins would be taken from the media all from the same culture. While the 
experimental section will go into further detail, Figure 2.3 depicts the workflow used for 
both the secreted proteins as well as the membrane-bound proteins.   
The membrane-bound proteins were included in the experiment for a few reasons.  
The first of which was to include the analyte that was previously used for studies.  All of 
the previously published data, referenced in Chapter 1, used only proteins extracted from 
the plasma membrane.42 The second reason was that we would be able to see if the array 
would classify both the secreted and membrane-bound proteins and if the array results 
would correlate well to one another.   If this correlation existed, the array could start 
being used with secreted proteins only rather than membrane-bound if using one versus 
the other was not losing information.  Being that there may be cellular changes from 
passage to passage with cell lines, it was important that the secreted proteins taken from 
the media was from the same flask that the membrane-bound proteins were taken.   This 
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would remove this possible variable that was present in the protein pre-study.
 
Figure 2.3: Experimental workflow for secreted proteins and membrane-bound proteins and glycoproteins.  
This workflow was used for all four human colon cell lines. 
The cells were cultured to approximately 70% confluence.  At this time, the 
media was removed and new media was added to begin the starvation process.  Recall 
that starvation indicates that FBS was not present in the media.  Antibiotics/mycotics 
were also removed.  After 48 hours of starvation the media was pipetted out of the flask 
and put in a separate tube (right branch of Figure 2.3), while the cells were scraped using 
PBS and put into a separate tube (left branch of Figure 2.3).  Trypsin was not used to lift 
the cells from the culture flask, as this would cleave the glycans on the cell surface.  
Continuing down the left branch of the above figure, the proteins were extracted from the 
plasma membrane using an extraction kit and then were fluorescently labeled with FITC.  
Prior to incubation the beads containing the SLs were washed with PBS twice. The beads 
were incubated with PBS containing 1% BSA for 15 minutes.  This solution was 
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removed and 1 mL of the protein solution at the desired concentration was added to nine 
tubes, each independently containing approximately 2 mg of a different SL (SL 1-9).  
After incubation, the beads were washed three times with PBS.  Each tube of beads was 
imaged using a fluorescence microscope, Leica® MZ 16F, using a GFP filter set.  The 
images are analyzed with a MATLAB® program.  
The right branch of Figure 2.3 represents the experimental workflow for the 
secreted proteins.  After removal from the flask, the media is centrifuged in order to 
remove cell debris.  After the centrifugation, the media is concentrated to isolate the 
secreted proteins while minimizing the liquid volume.  The secreted proteins are 
fluorescently labeled with FITC.   Prior to incubation the beads containing the SLs were 
washed with PBS twice. The beads were incubated with PBS containing 1% BSA for 15 
minutes.  This solution was removed and 1 mL of the protein solution at the desired 
concentration was added to nine tubes, each independently containing approximately 2 
mg of a different SL (SL 1-9). The beads were washed three times with PBS after 
incubation and before imaging.  
Figure 2.4 represents the data acquisition and processing after incubation with the 
SLs. This is the same workflow in Figure 2.1. Each tube of beads was imaged using a 
fluorescence microscope, Leica® MZ 16F, using a GFP filter set.  The images are 
analyzed with a MATLAB® program and process with Microsoft Excel®.  Following data 
processing, is data analysis using various statistical methods (i.e. LDA or PCA). 
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Figure 2.4: Data acquisition and processing workflow.  This is the same workflow depicted in the secreted 
protein pre-study. 
2.6 SECRETED PROTEIN STUDY DATA AND DISCUSSION 
The importance of this study was to investigate the usefulness of the synthetic 
lectin sensory array in a more clinically relevant way.  This would look at the ability of 
the sensor array to discriminate secreted proteins isolated from media in order to mimic 
the secreted proteins in blood or urine. The sensor array has already been shown to 
discriminate cell lines, seen in Chapter 1.  Similar cell lines would be used with the 
addition of a human colon cell line for a healthy/normal cell line.  The discriminatory 
power of the sensor array would be investigated for cell lines again as well as the secreted 
proteins. Table 2.3 depicts the cell lines used as well as the rep number and total number 
of data points for each sample. 
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Table 2.3: Table	Depicts all cell lines used in this experiment and the associated biological replicate number.   It 
includes the type of protein as well as the number of data points for each cell line.  Recall each technical 
replicate (N=1) is the response of nine synthetic lectins with a particular analyte 
 
There were two biological replicates done for each cell line for the secreted 
protein type, while there was one replicate done for each of the cell lines for the 
membrane bound proteins.  A biological replicate was one defined as at least two 
passages (cells split) and allowed to grow before being starved and scraped.  It is ideal to 
thaw two different cell stocks if possible.  Each cell line for the membrane bound proteins 
is listed as replicate 2 because the membrane bound proteins were taken from the cells 
that the media for replicate 2 was taken.  In other words CCD-841 CON rep 2 secreted 
proteins was the media taken from the flask of CCD-841 CON rep 2 cells.  Initially the 
 38 
experiment was designed to have two biological replicates for the membrane bound 
proteins as well, however, the entire membrane extraction kit was ineffective in 
producing any protein in the end.  After this experiment, it was decided not to re-grow 
cell lines as this is expensive and the utility of the sensor array with membrane proteins 
had already been established, as referenced in Chapter 1. 
All protein samples both secreted and membrane bound were dealt with as 
depicted in Figure 2.3 fluorescently labeled and incubated individually with SLs 1-9.  
The beads were then imaged using fluorescent microscopy in order to obtain bright 
numbers.  All of the data seen within this chapter is using normalized bright numbers.  
Figure 2.5 is the Linear Discriminant Analysis (LDA) plot generated from all of the data 
from secreted and membrane proteins listed in Table 2.3.   
 
Figure 2.5: Three class LDA plot generated with normalized bright numbers from the SL array generated by 
incubating fluorescently labeled secreted and membrane proteins. The leave one out classification accuracy was 
78% and the N=212.  The three classes used were healthy, cancerous non-metastatic, and cancerous metastatic. 
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Each data point represented in this plot is the sensor array’s response (SL1-9) 
with that particular analyte.  The discriminant analysis was run in Systat®, while the 
graph was generated using Statistica®.  LDA was used because the cell lines have well 
defined metastatic potential; therefore using a guided statistical method seemed 
appropriate.  The analysis used a three-class classification: healthy/normal, cancerous 
non-metastatic (lowly), and cancerous metastatic.  The green dots represent all of the 
healthy samples (CCD-841-CON), with the filled in denoting secreted protein and the not 
filled in representing the membrane-bound samples.  The orange triangles represent all of 
the cancerous non/lowly metastatic samples (HT29 and HCT116), with the filled in 
denoting secreted protein and the not filled in representing the membrane-bound samples.  
The red diamonds represent all of the cancerous metastatic samples (LoVo), with the 
filled in denoting secreted protein and the not filled in representing the membrane-bound 
samples.  The N for this particular analysis was N=212, representing the technical 
replicates within the biological replicates.   The ellipses surrounding the data points 
represent a 95% confidence interval for that particular data set.  The leave-one-out 
classification accuracy for this analysis was 78%. 
Ideally, it was hoped that the leave-one-out classification accuracy would be 
higher as was referenced in Chapter 1 in dealing with the membrane-bound proteins.  
Furthermore, it was initially hypothesized that in looking at the LDA plot that the 
secreted and membrane would overlap nicely.  While there is some overlap between the 
respective secreted and membrane protein of a particular metastatic potential, there is 
also some overlap of differing metastatic potentials leading to lower classification 
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accuracy.  However, thinking through the experiment and reviewing fluorescent 
intensities can explain this result. 
There are a few reasons why the LDA plots do not overlap above.  LDA attempts 
to group things that are alike together, but this is based up the SL array response, that is 
the response of SL 1-9 with one particular analyte.  Figure 2.6 depicts the fingerprint 
pattern from SLs 1-9 for HCT 116 membrane-bound proteins and secreted proteins.  The 
membrane bound proteins and secreted proteins were taken from the same biological 
replicate.  This plot is generated from normalized bright numbers. 
 
Figure 2.6: Fingerprint patterns for the membrane bound proteins and secreted proteins from the same HCT 
116 biological replicate.   As mentioned, in text, this was generated using normalized bright numbers.  
As can be seen from the figure, the patterns are slightly different.  This is just an 
example from one of the cell lines, but is a trend seen among most of the cell lines.  
Experimentally, the secreted proteins and membrane proteins require slightly different 
parameters.  Typically, when imaging the beads incubated with fluorescently labeled 
secreted proteins the exposure times used are longer than when imaging the beads 
incubated with fluorescently labeled membrane bound proteins.  The concentration of all 
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of the fluorescently labeled proteins incubated with the synthetic lectins were the same 
according to a BCA assay, however, there is a difference in the heterogeneity of the 
samples.  The membrane extraction kit used binds to plasma membrane proteins so that 
much of the sample is only plasma membrane proteins.  The secreted proteins are any 
proteins that are secreted off of the cells while in culture.  The proteins kept after the 
concentration of the media is above a 3kDa cutoff (the cutoff of the tubes used).  The 
latter approach provides a sample that is significantly more heterogeneous.  While all of 
the protein is labeled and quantified using a BCA assay perhaps only a portion of this 
protein would interact with the synthetic lectin.  Previous and current research in the 
Lavigne lab has demonstrated that glycoproteins interact through the boronic acid-diol 
interaction and some proteins have a protein/protein interaction with the synthetic lectin 
backbone.  With this in mind, it was advantageous to look at the LDA plots from both the 
membrane bound proteins (Figure 2.7) and secreted proteins (Figure 2.8) with the 
synthetic lectin sensor array separately.  Figure 2.7 depicts the LDA plot of the sensor 
array’s response with only membrane proteins from the four human colon cell lines.  
Recall there are two non-metastatic cell lines (HCT 116 and HT29) included in the non-
metastatic points (orange triangles). 
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Figure 2.7: Three class LDA plot generated with normalized bright numbers from the SL array generated by 
incubating fluorescently labeled membrane proteins. The leave one out classification accuracy was 97% and the 
N=69.  The three classes used were healthy, cancerous non-metastatic, and cancerous metastatic. 
Again, the discriminant analysis was run in Systat®, while the graph was 
generated using Statistica®.  This analysis also used a three-class classification: 
healthy/normal, cancerous non-metastatic (lowly), and cancerous metastatic.  The green 
dots represent all of the healthy samples (CCD-841-CON).  The orange triangles 
represent all of the cancerous non/lowly metastatic samples (HT29 and HCT116).  The 
red diamonds represent all of the cancerous metastatic samples (LoVo).  The N for this 
particular analysis was N=69, representing the technical replicates.  There is only one 
biological replicate in each of the cell lines.  The ellipses surrounding the data points 
represent a 95% confidence interval for that particular data set.  The leave-one-out 
classification accuracy for this analysis was 97%.   
The leave-one-out classification accuracy is significantly higher than the 78% that 
resulted from running the LDA analysis with both the secreted and membrane-bound 
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proteins.  It can be argued that there is increased classification accuracy because there is 
only one biological replicate, however it has been shown that the SL sensor array can 
discriminate membrane bound proteins/glycoproteins. There are two non-metastatic cell 
lines which cluster together (orange triangles) which indicates that while two different 
cell lines they SL sensor array data will group these by metastatic potential.  Both of 
these results were expected from the data mentioned in Chapter 1. 
Linear discriminant analysis was then run on only the sensor array’s response to 
the secreted protein from the four different cell lines.  The data set contains both 
biological replicates from each of the four human colon cell lines. 
 
Figure 2.8: Three-class LDA plot generated with normalized bright numbers from the SL array generated by 
incubating fluorescently labeled membrane proteins. The leave one out classification accuracy was 88% and the 
N=143.  The three classes used were healthy, cancerous non-metastatic, and cancerous metastatic. 
The discriminant analysis was run in Systat®, while the graph was generated using 
Statistica®.  This analysis again used a three-class classification: healthy/normal, 
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cancerous non-metastatic (lowly), and cancerous metastatic.  The green dots represent all 
of the healthy samples (CCD-841-CON).  The orange triangles represent all of the 
cancerous non/lowly metastatic samples (HT29 and HCT116).  The red diamonds 
represent all of the cancerous metastatic samples (LoVo).  The N for this particular 
analysis was N=143, representing the technical replicates.  There are two biological 
replicates in each of the cell lines.  The ellipses surrounding the data points represent a 
95% confidence interval for that particular data set.  The leave-one-out classification 
accuracy for this analysis was 88%.  The leave-one-out classification accuracy was very 
good for the SL array response with the secreted proteins.  This was a promising result 
for the clinical significance of the sensor array. 
All of the analyses were run with metastatic potential in mind, i.e., 
healthy/normal, cancerous non-metastatic (lowly), and cancerous metastatic.  However, 
in use as a diagnostic the most important question to answer is “Does the patient have 
cancer?”  If the answer to this is yes then there are a variety of imaging options that can 
be done in a follow-up setting, however that initial question would be answered.  It can 
also be argued that for a diagnostic it would not be idea to model secreted and membrane 
bound proteins in the same model.  In thinking about this question, the linear discriminant 
analysis was run on the secreted and membrane protein’s SL array response (Figure 2.5), 
however, this time using a two class method: healthy and cancerous.  
Looking at the three-class in Figure 2.5, it can be seen that the major source of 
overlap is between the cancerous non-metastatic and cancerous metastatic groups (both 
membrane-bound and secreted protein).  This overlap includes all of the orange data 
points (cancerous non-metastatic) and all of the red data points (cancerous metastatic).  
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Recall the leave-one-out classification accuracy for the three-class analysis (healthy, 
cancerous non-metastatic, and cancerous metastatic) was 78%.  If the analysis is re-run is 
a two-class analysis (healthy and cancerous) the classification accuracy improves to 90%.  
A graph cannot be drawn when performing a two-class analysis. Table 2.4 will 
summarize the linear discriminant analyses that were performed. 
Table 2.4: Summary of linear discriminant analyses performed and the associated leave-one-out classification 
accuracies.  The number of technical replicates is also listed.  Recall, every membrane-bound protein had one 
biological replicate, while, all secreted protein samples had two biological replicates. 
 
While it is interesting to look at the classification accuracies of membrane protein 
and secreted protein, an ideal diagnostic would be fluid-based to avoid an invasive 
procedure to obtain cells. 
2.7 CONCLUSION 
The initial sections of this chapter described the need for a fluid-based colon 
cancer diagnostic.  The synthetic lectin sensor array, up until this point, had only been 
used with membrane-bound proteins and glycoproteins.  This would not serve well in a 
clinical setting as obtaining cells from a tumor or polyp is as invasive as a colonoscopy 
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and would be associated with similar disadvantages.  With this in mind, optimizing the 
synthetic lectin sensor array for secreted proteins was essential. 
A proof-of-concept experiment was necessary to evaluate the whether the sensor 
array could discriminate secreted proteins, which would be used in a fluid-based 
diagnostic.  The experiment was optimized to use cell culture with four established colon 
cell lines of differing metastatic potentials varying from healthy to cancerous metastatic.  
The media was taken and concentrated for secreted proteins, while the cells were isolated 
to obtain the membrane-bound proteins and glycoproteins. The nine synthetic lectins 
were incubated with each fluorescently labeled analyte and imaged using fluorescence 
microscopy and camera.   
Linear discriminant analysis was used to analyze the data.  The secreted proteins 
and membrane bound proteins modeled together had a leave one out classification 
accuracy of 78%.  This was not completely unexpected as the secreted proteins are more 
heterogeneous and experimentally the SL array patters are slightly different.  The 
membrane bound proteins had a leave-one-out classification accuracy of 97% which was 
expected as former members of the Lavigne lab had determined the array was successful 
in discriminating cell lines of varying metastatic potential using membrane-bound 
proteins/glycoproteins.  The secreted proteins, when analyzed with linear discriminant 
analysis, had a leave-one-out classification accuracy of 88%.  This indicates that the 
synthetic lectin array was able to classify secreted proteins based on metastatic potential.  
The next section will describe the future experiments that could be done with the 
synthetic lectin array and clinical serum samples. 
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2.8 FUTURE WORK 
This proof-of-concept experiment shows great promise with the discrimination 
that was possible of the secreted proteins as well as the membrane-bound proteins.  To 
further the project, it is important to use the SL array with clinically relevant samples.  
The next step for this project would be to get clinical blood samples from colon cancer 
patients. 
The ideal route for the next step was to get serum samples from patients of 
varying stages of colon cancer.  Whole blood samples or serum samples could be used.  
Using serum samples would simplify the experimental procedure, however, if other 
experiments would require an analyte not present in serum then whole blood should be 
used.  There are a few companies that can give a serum sample, tissue sample from a 
tumor, and matched healthy portion of cells.  This would allow the investigation of 
whether serum samples or tumor samples provide a more accurate assessment of staging.  
Calculations should be done to determine a minimum number of samples needed to 
correlate the SL array to metastatic potential.  The lab already has healthy blood samples 
from volunteers in the lab as well as the Chemistry department at the University of South 
Carolina.  To mimic a clinically relevant diagnostic, albumin would be removed from the 
human serum samples as well.  Chapter 3 includes work done with mouse serum samples.  
It can be argued that a very similar protocol would be used for the human serum samples. 
2.9 EXPERIMENTAL METHODS 
Cell Culture 
Four human colon cell lines of varying metastatic potential were used for these 
experiments.  CCD-841-CON (ATCC® CRL-1790™) was the normal colon cell line used.  
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HCT-116 (ATCC® CCL-247™) and HT29 (ATCC® HTB-38™) were the cancerous lowly 
metastatic cell lines used. LoVo (ATCC® CCL-229™) was the highly metastatic cell line 
used.  This cell line was derived from the left supraclavicular region of a male.  All cell 
lines were grown according to ATCC® guidelines. 
Media Used 
HCT 116 and LoVo used a media of RPMI-1640 (purchased from HyClone 
SH30605.01, 10% FBS (50mL) purchased from VWR (45000-734) and 1% (5mL) 
antibiotics/antimycotics purchased from VWR (45000-616).  HT29 used a media made 
up of Dulbecco’s Modified Eagle Medium (DMEM) purchased from VWR (45000-734), 
10% FBS (50mL) purchased from VWR (45000-734) and 1% (5mL) 
antibiotics/antimycotics purchased from VWR (45000-616).  CCD-841-CON cells used 
Minimum Essential Media (MEM), 10% FBS (50mL) purchased from VWR (45000-734) 
and 1% (5mL) antibiotics/antimycotics purchased from VWR (45000-616).  The 
stockroom stocks some of this media. 
Remove 55mL of media from the bottle and place in a centrifuge tube.  This can 
be used this later for starving cells if needed.  Add the FBS and antibiotics/antimycotics 
in with a pipette rather than pouring the solution into the bottle.   After everything has 
been added to the media use a larger pipette and pipette up and down in order to 
thoroughly mix the media.  The previous steps can be performed with the media cold if it 
is not being used for anything after. 
Thawing Stocks 
Typically, the initial thaw of a stock will want to be done in a T25 flask.  Once 
you know that cell viability is high for a cell stock, you can thaw into a T75 flask.  If you 
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notice the T25 is confluent fast, the next time you can thaw into a T75.  Pre-warm your 
full media (all additives added) to 37˚C.  Make sure you have everything you need to 
thaw the cells in your hood ready to go, as DMSO is toxic to cells so they need to be 
thawed and thawed in a larger volume of media. 
Place about 5mL of warm media into a 15mL Falcon tube.  Pipette small amounts 
of warm media into the cryogenic vial.  You will need to pipette a small amount in and 
then pipette up and down.  As soon as some of the cell stock thaws place it into the falcon 
tube with the other warm media to dilute the DMSO.  Keep adding the warm media and 
removing the DMSO/cell solution to media until all of the stock has thawed.  The 
following day remove the media and add fresh media.  Be careful to not do this too soon 
after.  Dead cells and live cells look different yet they both float (dead cells will look like 
broken dark pieces where live unattached cells will look like nice healthy spheres).  I 
would usually split my cells 2-3 times before running any experiments to make sure these 
were healthy and viable.   
Feeding the Cells 
Feeding the cells requires the pipetting of old media off before putting new media 
on.  I would suggest changing the media every couple of days when not splitting the cells.  
The pink media will begin to turn orange when the cells are either too confluent or they 
media needs to be changed (you should not let it get to this point).  The media should be 
warm (37˚C) for this step. 
Splitting Cells 
The trypsin/EDTA media should be warmed in incubator to 37˚C before 
beginning the process of splitting the cells.  The cells should be at 70-75% confluence 
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prior to splitting.  Take the existing media off of the cells and put into the waste 
container.  The same pipette may be used as long as it does not touch the outside of the 
flask or any part of the hood.  Wash the back of the flask with 1-2 mL of the 
trypsin/EDTA solution then pipette this off and put into waste.  This will remove the dead 
cells and excess media that may not have come off with the first media removal.  Then 
(with a fresh pipette) add trypsin/EDTA to the flask.  The amount needed will depend on 
the flask size, but you want enough of the solution to cover the bottom of the flask when 
horizontal.  This will ensure that all cells will have the solution over them.  Place the 
flask back into the incubator (37˚C). 
The amount of time necessary to trypsinize the cells will depend on the cell line.  
In the beginning, check the cells every 1-2 minutes.  You can either hold the flask up to 
the light or look under the microscope to see if the cells are attached.  If you know that 
your cell line is hearty you can rub the back of the flask to speed up this process or in 
extreme cases hit the flask against your hand.  The cells should be floating when the have 
completely detached.  Be mindful not to leave too many cells behind, as this will deplete 
your cell number. 
Wash the cells that have detached to the bottom of the flask with fresh warm 
media.  This amount will depend on the size flask used.  The flask may need to be rinsed 
a couple of ties to ensure all of the cells have been removed.  Add this solution to a 15 
mL centrifuge tube and centrifuge for 4-5 minutes at 500 x g.  Be sure to not spin at too 
high of a rate as this will damage the cells.  Remove the supernatant and put in the waste 
container.  Add 1-2 mL of fresh media to the cell pellet.  Use a small pipette (p1000) and 
pipette this solution up and down.  This will ensure there are not clumps of cells when 
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adding to a new flask.  Add the appropriate amount of microliters to each flask depending 
on the split you want and how many flasks you need.  If there are extra cells these can be 
placed in the waste container.  Add the media to the flask to make it to the total volume 
for each flask type (5 mL for T25, 10 mL for T75, and 20 mL for T125.  The following 
day check to make sure the cells have attached and there are not too many floating cells.  
You can change the media if you would like using warmed media. 
Making Stocks 
Only make stocks from cells that are actively growing and no more than 75-80% 
confluent.  If you are unsure, split the cells again and makes stocks from the next 
passage.  One T75 flask should result in 3-5 stocks, however, adjust this number 
depending on how many cells you want in your stock.  I tend to put more in so that it is a 
better chance of recovery.  Cell stocks are frozen in cryovials that can be found in the 
stockroom.  Label each vial with you initials, cell line, and cell passage. 
Make sure everything is ready in the hood prior to these steps.  DMSO is toxic to 
cells so speed is required for this step.  Have a cooled solution of 20% DMSO in FBS 
(this should have been filtered through a .2 µm filter.  Trypsinize the cells according to 
the instructions above, inactivate the trypsin with media, and put into a centrifuge tube.  
Centrifuge the cell suspension for 4-5 minutes at 500 x g and remove the supernatant.  
The following steps you will want to use a p1000 pipette.  Re-suspend the cell pellet in 
the usual full media.  Add the amount you will need to have is .5 mL * the number of 
stocks you are making.  Be sure to pipette the solution up and down in order to equally 
distribute the cells into all of the vials.  Add .5 mL of the cell suspension to each cryovial 
and then add .5 mL of the 20% DMSO-FBS solution. 
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As soon as the DMSO is added the cells they must be frozen immediately.  The 
best way to do this is use the Mr. Frosty container and place in the freezer.  This will 
allow the temperature to reduce gradually.  The Mr. Frosty contains isopropanol that 
needs to be changed every five uses.  You can mark the top of the container with a 
marker in order to indicate which use it was. 
Starving the Cells 
When the cells reached no more than 70% confluence they were starved for 48 
hours.  The media did not include any supplements.  This was due to some cell lines 
dying when antibiotics were present.  For these first experiments, while we were unsure 
about the amount of media used ten T-75 or five T-125 flasks were used.  This would 
give about 100 mL of media.  In my notebook after the BCA it is seen that this gives back 
a tremendous amount of protein, much more than was needed for these or for repeat 
experiments.  As little as 5 mL of media has been used.  If the experiment requires cells 
in addition to the media the number of flasks needed is simply the number needed for 
cells.  The cell pellet will be the limiting factor.  
Concentration of Media for Secreted Proteins 
After 48 hours the media was taken off of the cells and centrifuged to remove cell 
debris.  The media was pipetted off and put in a new tube.  The media was centrifuged in 
Amicon® 3KDa centrifuge tubes (EMD Millipore).  This will be the longest step in the 
process.  Only 10-15 mL will be spun through every twenty minutes.  Keep this in mind 
when deciding on how many flasks to use.  When the media is mostly spun through and 
there is only a small amount in the bottom of the filter (be sure not to let the filter go dry) 
it is a good idea to rinse PBS through in order to get rid of all of the media. If colored 
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media is being used when the media is no longer colored and is a true clear you have 
finished the wash step.  If the media is colorless it will take a little more intuition to 
figure this out.  There should be a small amount of liquid in the filter tube (around 1500 
µL).  Pipette this out with a p200 pipette and tip (yellow).  Due to the filter size you want 
to make sure the pipette tip reaches the bottom because this is where the protein is.  After 
pipetting the solution out in a 15 mL centrifuge tube add PBS and rinse the filter pipetting 
up and down multiple times.  
Acetone Precipitation of Secreted Proteins from Media 
The protein is then precipitated with ice-cold acetone stored in the -30 degrees 
Celsius freezer.  Add four times the amount of acetone to the protein solution.  For 
example, if there is 2 mL of protein 8 mL of acetone would be added.  Shake the tube in 
order to see a white fluffy precipitate.  At this point, the protein solution can be stored in 
the -30 degrees Celsius freezer overnight if you wish or for a minimum of an hour.  The 
following day (or after some time) take the sample out of the freezer, spin it down, and 
remove the acetone.  Allow the centrifuge tube to sit in the hood for 30 minutes to an 
hour to make sure the acetone is completely evaporated.  At this point, the protein can be 
treated like any other protein sample.  Usually (if moving on to the labeling step), the 
protein is re-suspended in carbonate buffer using only the amount necessary to 
completely dissolve (starting with about 1 mL each time).  This will depend on the 
amount of protein recovered.   
Membrane Proteins and Glycoproteins 
The cells were scraped off the flask using a cell scraper.  We use a scraper in this 
step and not the trypsin because trypsin would cut the surface glycan chains off.  It is 
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good practice to put about 1 mL into the flask and scrape with cell scraper.  Use pipette 
this solution off and rinse with a second mL of PBS.  Scrape again and rinse the flask 
with PBS and the solution was centrifuged.  Hold the flask up to the light to make sure 
there are not a lot of cells left behind.  The PBS was taken off to leave behind a cell 
pellet.  This can be stored in the -30 degree Celsius freezer for a bit of time or in the -80 
degree Celsius freezer for an extended period of time.  The plasma glycoproteins and 
proteins were extracted using the Qiagen® Plasma Membrane Protein Kit. The protein at 
the end is in elution buffer and must be spun into carbonate buffer purified using 
Amicon® 10K centrifuge (spin) tubes (EMD Millipore).  The solution was put into the 
spin tube and spun for about 8 minutes at 4000g.  The time spun may change depending 
on protein concentration, but you want to spin until it is at the “2” line on the tube.  When 
the solution is at the “2” line, 1.5 mL of carbonate buffer is put in the exchange tube and 
spun for 5 minutes.  Again it is checked to make sure the solution is at the “2” line.  At 
this point, you want to turn the small tube inside over and spin out into a micro centrifuge 
tube in a bench-top centrifuge.  Put in 300 µL of carbonate buffer and pipette up and 
down.  It is advantageous to use a yellow tip again for this step in order to get all the way 
down in the filter.  Turn tube over and spin again. Rinse tube with 2-100 µL increments 
of carbonate buffer.  
Labeling of Membrane and Secreted Proteins/Glycoproteins 
The membrane proteins/glycoproteins and secreted proteins were labeled 
separately with fluorescein isothicyanate (FITC) in DMF and carbonate buffer.  2.8 mg of 
FITC was dissolved in 100 µL of DMF.  10 µL of the FITC solution was put into 200 µL 
of protein.  The total volume of the solution was brought up to 600 µL by adding 400 µL 
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of carbonate buffer.  The protein solution was tumbled for 1 hr at 37 degrees Celsius and 
purified using Amicon® 10K centrifuge (spin) tubes (EMD Millipore).  The solution was 
put into the spin tube and spun for about 8 minutes at 4000g.  The time spun may change 
depending on protein concentration, but you want to spin until it is at the “2” line on the 
tube.  When the solution is at the “2” line, 1.5 mL of PBS is put in the exchange tube and 
spun for 5 minutes.  Again it is checked to make sure the solution is at the “2” line.  At 
this point, you want to turn the small tube inside over and spin out into a micro centrifuge 
tube in a benchtop centrifuge.  Put in 300 µL of PBS and pipette up and down.  It is 
advantageous to use a yellow tip again for this step in order to get all the way down in the 
filter.  Turn tube over and spin again.  If you are using secreted proteins you can repeat 
the rinse step since there is a large concentration of protein.  If you are using membrane 
extracts you would want to be aware that there is not as big of a concentration and thus 
maybe rinse with 2-100 µL increments of PBS.   After labeling a BCA assay was done to 
quantify the amount of protein. 
BCA Assay 
Thermo Scientific BCA kit was purchased from VWR.   
Sample Preparation 
If using secreted protein sample you may need to dilute your samples and run 
these with the concentrated sample to ensure the concentration falls within the range of 
the assay. If this BCA assay is done before labeling, the samples will be in carbonate 
buffer, thus your standards should be made in carbonate buffer.  If this BCA is done after 
the labeling steps, the samples will be in PBS and thus your standards should be made in 
PBS. 
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Standard Preparation 
There is a standard 2 mg/mL solution included with the kit.  Put 100 µL of this 
solution into a small plastic tube.  Put 50 µL of carbonate buffer in several other tubes.  
Then take 50 µL of the 2 mg/mL solution in the first tube.  Be sure to vortex this several 
times (This is the first 1:2 dilution).  Then take 50 µL of that solution and put it in the 
next tube.  Continue this process.  Make sure you also have a blank standard (either 
carbonate buffer or PBS depending on what step you are doing this). 
Reagent Preparation 
 The directions instruct you to make the reagent to be made 50:1.  200 µL of 
reagent is required for each well so the amount of total reagent will need to be calculated 
(200 µL x # of wells).  This can be done in a 15 mL centrifuge tube. 
Well Preparation 
 Make sure the standards/samples are done in triplicate.  Put 10 µL in each well of 
standards and samples.  Then put 200 µL of reagent in all of the wells.  Make sure to then 
mix each well with a pipette tip.  The plate should then be placed in the oven for 30-45 
minutes at 37 degrees Celsius.  Periodically check your plate to see if the standards have 
changed.  The plate is then read on the plate reader at 562 nm.  Be sure not to leave your 
plate for a long period of time.  It should be noted that this assay is not an endpoint assay 
and will continue to develop. 
Synthesis of Synthetic Lectins 
SLs are attached to Tentagel beads.  The beads are weighed out and put in 10mL 
of DMF(dimethylformamide) for ten minutes in order to swell the beads.  Meanwhile, 
Fmoc-Met-OH(10eq) is activated with HBTU(10eq) for 10min in 5% N-
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methylmorpholine in DMF.  The amino acid solution is added and tumbled for 1 hour.  
The solution is drained and the beads are washed with DMF, MeOH(methanol), DMF, 
MeOH.  After the last washing, a ninhydrin test is performed on one or two beads to see 
if the amino acid has coupled.  If coupled, the Fmoc group is removed using 10mL of 
20% piperidine in DMF.  That process is repeated manually until the amino acids are on 
or a peptide synthesizer can be used.  The SL is then N- terminally acetylated using 
10mL of CH2Cl2 containing 5% pyridine and 5% acetic anhydride. 
Removal of protecting group on DAB (diamino acid)  
Diamino acid (DAB) has an ivDde protecting group on it.  In order to put on the 
boronic acids, these must be removed.  The protecting group is removed by adding 10mL 
of 2% hydrazine monohydrate in DMF and tumbling for 1 hour. 
Addition of Phenyl Boronic Acids (PBA) 
2-formylphenyl boronic acid (8eq) is dissolved in 10% MeOH in DMF.  
Activated 3Å molecular sieves and the PBA solution are added to the beads and tumbled 
overnight at 37 degrees Celsius.  Sodium borohydride (NaBH4) (8eq) is added and gas 
was released over 30 min.  The beads then tumble for 4 hours.  The beads are washed 
with DMF and MeOH and the sieves are removed.  The beads are then washed again. 
Removal of Acid Labile Groups 
In order to remove the acid labile groups the beads are tumbled with 10mL of 
95% trifluoroacetic acid(TFA), 2.5% water, and 2.5% triisopropylsilane for 1 hours.  
After tumbling, the solution is taken off and washed with DMF, MeOH twice.  The 
synthetic lectins can then be washed with PBS three times in order to cut down on PBS 
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wash time done before incubation.  After washing with PBS it is important that the tubes 
of SLs be place in the refrigerator and not the -30 degrees Celsius freezer. 
MALDI Sample Preparation 
Phenyl Boronic Acid (PBA) Group Removal 
This step can be avoided if a small amount of beads are taken out before the 
boronic acids are added.  Once removed, the rest of the SL synthesis steps are followed 
on the small amount of beads.  However, if the boronic acids are still attached and a 
MALDI is needed to be run these groups will need to be removed. 
Remove PBA groups by add 100 mmol solution of H2O2 to the 1.5 mL centrifuge 
tube containing the beads.  Put this tube at 50 degrees Celsius for 1hour.  After the hour, 
wash the beads with dH2O three times.  Add 50 µL of a 40 mg/mL solution of Cyanogen 
Bromide (CNBr) made in .1M HCl.  Make sure all work with CNBr is done in the hood.  
Place this solution in the dark (usually your drawer) for 15-18 hours.  Evaporate this 
solution using the speed vacuum centrifuge.  There should be a small amount of white 
substance at the bottom of the centrifuge tube. 
MS Sample 
 Dissolve the sample obtained from the previous section in 10 µL of .1% TFA in 
H2O.  In order to make the matrix, make a saturated solution of α-cyano-4-hyroxy 
cinnamic acid (CHCA) in 50:50 acetonitrile/.1 % TFA in H2O.  Add 1 µL of sample to 
the desired spot on the plate for MALDI.  Add 1 µL of matrix to the same spot.  Pipette 
the 2 µL of solution up and down a few times to get a good mix of matrix and sample.  
Let the plate dry and take obtain MALDI spectra. 
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Incubation with Synthetic Lectins (SLs) 
 Each synthetic lectin is weighed into a centrifuge tube (2mg) for the binding 
study.  The beads were washed with PBS twice and PBS with 1% bovine serum albumin 
(BSA) for 15 minutes.  This solution was removed and 1mL of .0002 mg/mL (50 fold 
dilution of a .1 mg/mL solution) of a particular protein is put in the tube and allowed to 
incubate overnight at room temperature.  The solution was removed and then washed 
with PBS three times.  After the last wash, the beads are re-suspended in about 500 µL of 
PBS to make the exchange to the microscope slide easier.   
Imaging the Beads 
The beads are imaged with a fluorescence microscope, Leica MZ 16F, using a 
GFP filter set.  It is imperative that all of the SLs in each cell line (in this case SL 1-9) 
were imaged at the same exposure time.  In order to do this, place each slide under the 
microscope and find the brightest SL.  Once this is found for a particular sample, 
optimize this slide to have the largest green value without saturating the camera (no more 
than 190 to be safe, 255 is the absolute max).  This number can be found by circling a 
bead in Adobe Photoshop® and pulling up the histogram information. After finding the 
appropriate exposure time, pictures can be taken with care that most beads are within the 
Region of Interest (ROI) and not touching one another, as these beads would be thrown 
out. 
Data Analysis 
After the pictures have been taken they must be converted into JPG or JPEG as the 
camera takes these pictures as TIFF files.  There are protocols written in the lab to do this 
on a MAC or PC.  After conversion into jpeg, the files can then be run through a code in 
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MATLAB® written by Dr. Greytak and modified by Anna Veldkamp.  The code used for 
these experiments was image analysis anna.  There is a protocol written in the lab that 
walks a user through the necessary steps to run the code.  This code essentially picks out 
each bead and provides information about area, bright number, red number, green 
number, and blue number.  It also gives information about where this bead was located in 
the picture so that you can identify a number for each bead.  The data is processed in 
excel and outliers are removed (1.5 IQD) in order to get the array information for the SLs 
with each protein type.  At this point, the data can be put into varying statistical models, 
the most common seen in this chapter are linear discriminant analysis (LDA), principal 
component analysis (PCA), and machine learning which is an extension of linear 
discriminant analysis (LDA). 
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: INVESTIGATING METASTATIC POTENTIAL WITH AN CHAPTER 3
ISOGENIC CELL LINE  
3.0 ABSTRACT 
The utility of the synthetic lectin array has been shown for existing cell lines in 
both chapters 1 and 2, however, questions arise about the utility of the sensor array in a 
clinical setting.  The cell lines used in the previous chapters had an established metastatic 
potential, meaning that these cell lines were either classified as healthy/normal, cancerous 
non-metastatic (lowly metastatic), or cancerous metastatic.  In a clinical setting a patient 
may be undergoing metastatic changes as cancer progresses.  It would be helpful to know 
the usefulness of the array in terms of diagnosing metastatic potential as it is changing.  
The first part of this chapter will discuss the metastatic reversion of an isogenic cell line, 
while the second part of this chapter will discuss the synthetic lectin array as a diagnostic 
in an in vivo longitudinal mouse study. 
3.1 INTRODUCTION 
Previously, the synthetic lectin array has been investigated for use in diagnosing 
colon cancer using cell lines.  This was done using membrane bound proteins, referenced 
in Chapter 1, and secreted proteins, referenced in Chapter 2.  This chapter will focus 
using the synthetic lectin array as a tool in investigating metastatic potential.  This 
chapter will be split up into two parts.  The first part will discuss investigating the 
reversion, in metastatic potential, of an isogenic cell line.  The second part will discuss 
the use of the same isogenic cell line in a longitudinal mouse study.  
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3.2 PART 1: INVESTIGATING REVERSION OF METASTATIC POTENTIAL 
Dr. Peña’s lab modified an existing cell line, CT26, in vivo.  CT26 is a lowly 
metastatic cell line with a metastatic rate of approximately 0-5%. CT26 cells were 
injected into a mouse cecum and some metastatic cells migrated to the liver, as is the case 
with most colon cancer.  These cells were taken from the tumor sites upon the sacrificing 
of the mice and cultured.  The new cells were then cultured and injected into the cecum 
of new mice.  This process was repeated for three rounds in order to obtain what was 
called CT26-FL3, a highly metastatic cell line. 
 
Figure 3.1: A) Picture of the internal organs of a mouse.  The cecum is highlighted which is where the cells were 
injected. B) Pictorial representation of the experimental procedure Dr. Pena's lab used in order to make CT26-
FL3 cells. 
Figure 3.1a shows the internal organs of a mouse, noting that the cecum is where the cells 
were injected.  Figure 3.1b depicts the process of in-vivo selection, which was how the 
Pena lab created a highly metastatic cell line, CT26-FL3, from a non-metastatic parent 
Cells	taken	from	
tumors	upon	
sacriﬁcing	mice	
and	injected	in	
new	mice	
a	
b	
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line CT26.49  Dr. Peña’s group noticed, through invasion assays, that after 3-5 passages 
CT26-FL3 began to revert back to the metastatic potential of the parent cell line, CT26.  
Table 3.1: Comparison of CT26 and CT26-FL3 cell lines.  This table contains metastatic potential information 
for both cell lines, as well as metastatic potential information after 3-5 passages. 
 
Table 3.1 compares CT26 and CT26-FL3 in terms of metastatic potential prior to 
cell culture passages, as well as metastatic potential after 3-5 cell culture passages.  As 
discussed in Chapter 1 glycans have a role in metastasis, particularly sLex has a role in 
the intravasation and extravasation of the cells from a primary tumor site to a secondary 
tumor site.21 With this in mind, the questions that were hoping to be answered were: does 
this reversion have something to do with glycosylation? and Can the metastatic reversion 
be probed with the synthetic lectin array?   
3.3 PART 1: EXPERIMENTAL WORKFLOW 
While the experimental section of this chapter will go into further detail about the 
specifics in terms of sample workup, it is important to highlight the general method for 
probing the above-mentioned questions.  The same workflow that was used in Chapter 2 
was employed in these experiments and is depicted in Figure 3.2. 
CT-26	 CT26-FL3	
Cell	Line	 Parent	Cell	Line	 Modiﬁed	Cell	Line	
Type	 Colon	Cancer	 Colon	Cancer	
Metasta5c	Poten5al	 Non-metasta5c	0-5%	
Highly	metasta5c	
Approx.	95%	
Metasta5c	Poten5al	aCer	
3-5	passages	 0-5%	
Reverts	back	to	CT26	
(0-5%)	
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Figure 3.2: Workflow used for reversion of CT26-FL3 experiments. 
These cells retrieved from the mouse were identified as CT26 +1, where the +# 
indicates the passage number.  While the experimental workflow depicted above was 
followed, in the beginning of these experiments (the early passages) there were not 
enough cells in order to do a membrane extraction.  When possible, a membrane 
extraction was done on the cells, however for this reason the chapter will mainly discuss 
the use of secreted proteins in the experimental as well as in the data analysis sections.  
As in Chapter 3, the SLs used for the experiments in this part were SLs 1-9.  For 
convenience the sequences are listed again in this chapter in Table 3.2. 
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Table 3.2: Sequences for SLs 1-9. 
 
The following section will discuss the experimental results as well as the associated 
discussion. 
3.4 DATA ANALYSIS AND DISCUSSION 
CT26-FL3 +1 was obtained from the Peña lab.  This sample needed to be split in 
order for the subsequent passages to be grown.  Secreted protein samples were from 
CT26-FL3 +2 through CT26-FL3 +10 with the exception of CT26-FL3 +6.  There were 
issues with the cell culture of this passage; however, subsequent passages were grown 
without a problem.  Recall, that each protein solution (from the passage) is incubated 
with SLs 1-9.  Figure 3.3 depicts the Principal Component Analysis (PCA) of the SL 
array’s response with each protein sample.  Each data point represents the response of 
each SL’s interaction with the fluorescently labeled protein.  As discussed in Chapter 1, 
rather than looking at the fingerprint pattern of each SL’s response with each proteins 
sample it is easier to employ various statistical methods.   
Principal Component Analysis is a statistical method employed throughout this 
chapter of the dissertation.  It is similar to Linear Discriminant Analysis (LDA), 
discussed in Chapter 1, in that the program is attempting to group similar things together 
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and different things apart.  However, the main difference between LDA and PCA is that 
PCA is unguided.  Therefore, the statistical program does not know that CT26-FL3 +2 is 
different than CT26-FL3 +3.   
 
Figure 3.3: Principal Component Analysis (PCA) of secreted proteins from CT26-FL3 passages. 
Principal Component Analysis was used in this case because unlike the cell lines 
used in Chapter 1 and Chapter 2, we did not know the metastatic potential of each 
passage.  The only information that was known is that the Peña lab saw a metastatic 
potential reversion around passage 3-5.  Therefore, PCA could be used to understand how 
the different samples grouped.  With this method it was possible to extract information 
about the samples and how they are grouped.  In looking at Figure 3.3, it can be seen that 
there are two distinct populations.  CT26-FL3 passages +5, +7, +8, +9, and +10 are one 
population, while CT26-FL3 +2, +3, and +4 are the other population.   
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Figure 3.4: PCA plot seen in previous figure with circles added to indicate possible groupings. 
Figure 3.4 is the same PCA plot from Figure 3.3 with the addition of the black 
circles indicating the initial groupings that were seen.  These groupings correlate to the 
observations seen by the Peña lab.  Recall, the metastatic reversion took place somewhere 
between 3-5 passages.  These groupings place CT26-FL3 +5 through CT26-FL3 +10 
together and CT26-FL3 +2 through CT26-FL3 +4 together.  With the invasive 
information from the Peña lab, it can be assumed initially that passages +2 through +4 
would be highly metastatic with +5 through +10 as non-metastatic. 
To look at these groupings further, linear discriminant analysis (LDA) was used.  
Recall, this is the guided statistical method in which the computer program creates a 
model based on the information given about each group. Figure 3.5 shows the LDA plot 
of this data. 
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Figure 3.5: LDA plot of CT26-FL3 passages modeled with a healthy cell line (CCD-841 CON) N=116 and the 
leave one out cross validation was 98%. 
All of the data depicted in the PCA plot was from secreted proteins.  Therefore, 
the healthy cell line data is based on the sensor array’s interaction with secreted proteins 
from CCD-841 CON, a healthy/normal colon cell line.  The information put into the 
model was that CT26-FL3 +2-CT26-FL3 +4 was identified as cancerous metastatic and 
CT26-FL3 +5-CT26-FL3 +10 was identified as cancerous metastatic.  The model created 
is what will be called 3 class, which means each point was identified in the program as 
healthy, cancerous non-metastatic, and cancerous metastatic.  The N=116 for this data set 
and the leave-one-out cross- validation accuracy was 98%.  This is obviously a high 
classification accuracy, however, it can be argued that this was to be expected as the 
groupings were decided based on where they fell in the PCA plot (which was unguided).   
To validate these groupings, sensor array data was added that included known 
metastatic (LoVo) and non-metastatic (HCT 116 and HT29) secreted proteins.  This LDA 
plot is seen in Figure 3.6. 
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Figure 3.6: LDA plot of CT26-FL3 passages modeled with a healthy cell line (CCD-841 CON), non-metastatic 
cell lines (HCT 116 and HT29) and metastatic cell line (LoVo). N=149 and the leave one out cross validation was 
97%. 
Adding this information will allow the visualization of the CT26-FL3 passages along 
with the cell line data to validate the groupings that were identified in the PCA graph.  
Again, this plot was generated by using a three-class classification accuracy: 
healthy/normal, cancerous non-metastatic (lowly), and cancerous metastatic.  It can be 
seen that the CT26-FL3 passages, whether assigned cancerous non-metastatic or 
cancerous metastatic are grouping with the secreted protein of that metastatic potential.  
The N=149 for this plot and the leave-one-out classification accuracy was 97%. 
3.5 CONCLUSIONS AND FUTURE WORK 
The information presented in the first part of this chapter indicates that the 
reversion may be seen from the glycosylation standpoint.  The array can is able to group 
the 9 passages into two populations.  With the metastatic reversion information from the 
Peña lab, it is possible to extrapolate the metastatic potential after subsequent passaging. 
There are a variety of directions this project could be taken.  The first would be to 
repeat these experiments beginning with CT26-FL3 +1 and passaging through CT26-FL3 
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+10.  To externally verify the metastatic potential of each passage, invasion assays could 
be performed.  Dr. Peña’s lab has performed these assays, however, the invasion assays 
would need to be re-done in conjunction with the cell culture passages and sensor array 
data.  Figure 3.7 depicts a general protocol of an invasion assay as well as general results.   
 
Figure 3.7: Invasion assay. a) pictorial representation of an invasion assay being performed. b) Both pictures are 
the bottom of the trans-membrane well of an invasion assay. The left picture is a photograph of a non-invasive 
cell line after an invasion assay and the right picture is a highly invasive cell line after an invasion assay. 
Figure 3.7a50 depicts the overall scheme of an invasion assay.  A trans-membrane 
well is used that has a layer of matrigel in it.  This matrigel mimics the basement 
membrane that a cell would need to migrate through in the body.  The cells are starved 
for 24 hours and placed in the top of the well.  A chemo attractant is placed in a chamber 
below the well, in this case, it would be media with FBS added, as the cells that can move 
would move to where the supplement is.  The cells are incubated or 24 hours.  The 
picture on the right of Figure 3.7a mimics the result of the invasion assay with a mixture 
of invasive and non-invasive cell lines.  In this case, the green cells would be the cells 
with the invasive properties.  After the incubation the cells are stained and imaged.  
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ASSAY FOR QUANTITATING INVASIVENESS OF TUMOR CELLS
Invasion Chamber Matrix Barrier
Filter Underside:
Non-Invasive Cells
Filter Underside:
Invasive Cells
Fig. 1. Invasion assay: Boyden chamber assembly used for the invasion assay is shown in the upper left, section of a matrigel-coated (SOÂ«igprotein) filter is shown
in the upper right, lower surfaces of an invasion membrane when NIH 3T3 (lower left) and T24/3T3 (lower right) are assayed for invasion.
shown). When matched cell lines were examined, such as 3T3
and 3T3 transfected with ras (Fig. 3) and the invasive and
noninvasive lines from the 1735 melanoma clones C110 and
M2 (data not shown), we found that the chemotactic response
of the malignant cell was somewhat greater than its control line
(1.5 to 2 ti es), but that invasiveness was some 15-fold greater.
These results indicate that both the noninvasive and invasive
cells are able to migrate to chemoattractants and that the
basement membrane represents the critical barrier in our assay.
Studies on Prostate Cells. We also tested several human
prostatic epithelial cell lines for their invasive activity in vitro
and for their metastatic capability in vivo. These cells were
studied because they represen a graded seri s differing in their
malignancy in the human and in their metastatic abilities in
nude mice. Normal prostatic cells did not invade the basement
membrane matrigel nor form mÃ©tastasesin the nude mouse
(data not shown). Primary benign hyperplastic prostatic cells,
which did not form tumors in the animal after intrasplenic
assay, were not invasive (Table 2). The prostatic carcinoma line
(Du 145) gave rise to local tumors but showed base-line levels
of invasiveness in vitro and very little metastatic activity in vivo.
In contrast, cells from the rare liver metastasis of the Du 145
line, designated Du LM, and a highly malignant prostate tumorline, PC 3, invaded the matrix and also formed mÃ©tastases/"/;
vivo. The organs involved were liver, parietal peritoneum, mes-
enteric and mediastinal lymph nodes, and lung parenchyma.
T is suggests that the in vitro invasion assay may supplement
the intrasplenic assay for detecting metastatic variants and for
quantitating metastatic potential.
No morphological differences were noted in the appearance
of the various lines of human prostate cells whether normal or
alignant when cultured on plastic substrates. However, when
plated onto a matrigel substrate, the cells showed striking
differences. Under these conditions, the normal cells formed
secretory domes and the low-grade carcinoma cells aggregated
into tight colonies. In contrast, the metastatic lines extended,
spread, and formed branching, invasive colonies (Fig. 4, right).
This distinctive behavior was apparent after 24 to 48 h in
3241
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Figure 3.7b51 is a photograph and what the results would look like when comparing an 
invasive cell line (right) with a non-invasive cell line (left).  Ideally, these experiments 
would verify what the sensor array data and the PCA plot indicate, two populations 
indicating a change in metastatic potential from the glycosylation pattern point of view.   
Another addition to this project could be the use of natural lectins.  What is 
assumed is that because the SL sensor array is binding with sugars there has to be a 
different response because of aberrant glycosylation.  While extremely selective, natural 
lectin arrays could be used to discover which glycans are changing between the passages 
(if there is a natural lectin to detect this sugar).  Because there is such a high correlation 
between sLex and metastasis this could be one sugar to potentially investigate.  The 
natural lectin information could then be combined with the SL array information in order 
to create a better picture of what is happening throughout the metastatic reversion from 
the glycosylation side of things.  
3.6 PART 2: INVESTIGATING METASTATIC POTENTIAL IN AN IN-VIVO 
MOUSE STUDY 
The second part of this chapter will focus on using CT26-FL3, highly metastatic 
cell line, and CT26, a lowly metastatic cell line, for a longitudinal mouse study.  The aim 
of this study was to determine if the sensor array could detect glycosylation changes from 
what is secreted by the tumor into the vasculature.  It was also to determine if the sensor 
array can differentiate the cancerous from non-cancerous mice and when the disease 
became metastatic.  The experimental workflow section of this chapter will discuss the 
basic set-up and collections, while the experimental section will discuss the intricate 
details of each part of this experiment.  
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3.7 PART 2: EXPERIMENTAL WORKFLOW 
It should be mentioned that Dr. Peña’s lab did the mouse work for all of the 
experiments discussed.  While I was present for most of the blood draws and the final 
sacrificing and weighing, I am grateful to the Dr. Peña and all those in her lab for taking 
on the workload of the mouse study.  
The study involved the use of fifteen mice. Table 3.3 provides the four types of mice as 
well as the condition of each mouse.  The mice used were Balb/c mice. 
Table 3.3: Mouse conditions and information for longitudinal mouse study. 
 
The control mice had no procedures done to them.  Because aberrant 
glycosylation occurs with inflammation the sham mice were included in the study.  The 
sham mice had the same incision as the CT26 and CT26-FL3 mice, however, they did not 
have any cells injected, but rather were opened up and closed back up.  The CT26 mice 
had surgery and the lowly metastatic cells injected, while the CT26-FL3 mice had 
surgery and the highly metastatic cells injected.  All of the mice were subjected to a pre-
bleed before any surgery happened.  This blood draw happened at the eye of the mice on 
average every 5-7 days.  The blood was spun down and the serum samples were given to 
Name	
Number		
Of		
Mice	
Cells	
Injected	
Metasta6c	
Poten6al	
Condi6on	
Details	
Control	 3	 None	 N/A	 None	
Sham		 4	 None	 N/A	 Surgery,		no	injec9on	
CT26	 4	 CT26	 0-5%	
Surgery,	
CT26	
injected	
CT26-FL3	 4	 CT26-FL3	 >95%	
Surgery,	
CT26-FL3	
injected	
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the Lavigne lab. Table 3.4 shows the exact days of the experiment and what associated 
event took place.  The experiment lasted a total of 47 days.  It should be noted that one of 
the CT26 mice died during the experiment. 
Table 3.4: Specific blood draws and surgery days for the longitudinal mouse study. 
 
For ease of explanation, the "day” will refer to the blood draw as on the day of the 
surgery no blood was taken.  Each blood draw from the mouse resulted in about 50 µL of 
serum except for the sacrifice blood draw, which was about 150 µL of serum as there was 
no risk of harming the animal by taking too much blood. 
For reasons summarized in Chapter 2, one of the major concerns initially was 
being sure that the albumin was removed from the blood samples.  With this in mind the 
first step in the experiment was to use a Pierce™ albumin depletion kit (Product #85160) 
in order to remove the albumin.  Following this, the sample was spun into carbonate 
buffer, fluorescently labeled with FITC, and a BCA assay was done in order to quantify 
protein concentration.  After the BCA, the sample was then spun into PBS and a BCA 
was done again to determine the amount of sample needed to use a 50-fold dilution of .01 
mg/mL.  
Day Date Event 
1 5-29-15 Blood Draw 
N/A 6-1-15 Surgery 
2 6-5-15 Blood Draw 
3 6-10-15 Blood Draw 
4 6-18-15 Blood Draw 
5 6-25-15 Blood Draw 
6 7-2-15 Blood Draw 
7 7-9-15 Blood Draw 
8 7-14-15 Blood Draw (sacrifice) 
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Unfortunately, after a large portion of the mouse samples had been depleted it was 
noticed that the kit purchased was not meant for mouse samples.  It had said that it would 
not be effective for mouse samples. Rather, than starting over and using more of the 
mouse sample, the SL array response with both experimental set-ups: using the albumin 
depletion kit and not using the albumin depletion kit.  Ideally, if the kit is not effective 
with mouse samples then it will not affect the sample’s response with the synthetic lectin 
array.  This experiment was done in order to know if the “albumin depletion” had to be 
done to keep everything consistent or if the following samples could be run without this 
step.  It should be noted that taking out the albumin depletion would significantly reduce 
sample work-up.  Figure 3.8 is a flow chart of both experimental options. 
 
Figure 3.8: Experimental flow chart of both experimental options for the mouse serum samples.  A) represents 
the experimental work-up if the albumin depletion kit is not used.  B) represents the experimental work-up if the 
albumin depletion kit is used. 
Figure 3.8b was initial experimental set up.  The albumin was depleted using the 
depletion kit.  After the kit was used, the serum was in a wash buffer.  The solution was 
Serum	Sample	
Deplete	albumin	
from	serum	with	
kit	
Spin	into	
carbonate	buﬀer	
Dilute	serum		
into	carbonate	
Buﬀer	(600	µL)	
Fluorescently	
label	with	FITC	
Fluorescently	
label	with	FITC	
Spin	into	PBS		
and	incubate	
with	SLs	1-9	
Spin	into	PBS		
and	incubate	
with	SLs	1-9	
15	µL	15	µL	
A	 B	
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then exchanged using Amicon® 10K centrifuge (spin) tubes (EMD Millipore) in order to 
have the serum sample in carbonate buffer.  The sample was labeled with FITC and the 
solution was exchanged to be PBS prior to a BCA assay and incubation with SLs 1-9.  
Figure 3.8a depicts the second experiment designed to validate the albumin depletion kit 
use.  In this step, the serum sample was diluted directly into 600 µL of carbonate buffer.  
The sample was labeled with FITC and the solution was exchanged to be PBS prior to a 
BCA assay and incubation with SLs 1-9 exactly as it was done in Figure 3.8b.  Figure 3.9 
shows the fingerprint pattern for each experiment (A and B) for the mouse 3-M1.  This 
mouse was one of the CT26-FL3 mice.  This sample was chosen because there was a 
large amount of serum from this draw. 
 
Figure 3.9: Fingerprint patterns from SL s 1-9.  3M1 is the mouse used.  3M1-A is experiment A from the flow 
chart above where no albumin depletion was performed.  3M1-B is experiment B from the flow chart above 
where albumin depletion was performed. 
3M1-B is the fingerprint pattern for the protocol that used the albumin depletion 
kit, while 3M1-A is the fingerprint pattern for the protocol that did not use the albumin 
depletion kit.  The error bars represent the standard deviation for each SL.  It should be 
noted that all percent standard deviations were below 15%.  Looking at the fingerprint 
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patterns above, it can be seen that 3-M1A and 3-M1B have relatively similar patterns.  
With this information, it was decided that the experiment could move on without the use 
of the albumin depletion kit.  The advantage of this was that the albumin depletion was a 
time consuming step and only a few samples could be done at a time with one person.  
Within the data analysis section, it will discuss which samples have been processed with 
the albumin depletion kit and which samples have not if it pertains to the graph presented. 
3.8 DATA ANALYSIS AND DISCUSSION 
With such a large number of samples [(15 mice)(8 blood draws) = 120 serum 
samples)], there had to be an overall plan for how the serum samples would be processed.  
It was decided to initially investigate the first day and the last day of the experiment.  
This would compare the blood draw from the pre-bleed, which was before any surgery 
(day 1), with the blood draw from the final sacrifice day (day 8).  This would roughly be 
about 30, recall one mouse died during the experiment, so in actuality it was 29 samples.  
As this was the first set up samples that were worked with all of them went through all of 
the samples went through protocol B, which involved the use of the albumin depletion 
kit.  In the graphs this will be listed as day 1 and day 8, as it is in Table 3.4.  This seemed 
an obvious place to start, as this should be the biggest difference in glycosylation 
patterns. Aberrant glycosylation begins at the onset of cancer and continues to change as 
the disease progresses.  Figure 3.10 shows the PCA plot of the SL array’s response with 
all day 1 (pre-bleed) and day 8 (sacrificing bleed) samples. 
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Figure 3.10: PCA plot of day 1 (pre-surgery bleed) and day 8 (sacrificing bleed). 
 Each data point represented in the plot is from the response of SL 1-9 with that 
sample.  The values used were raw bright numbers from the sensor array.  Principal 
component analysis was chosen because it is an unguided method.  We did not know 
what samples represented what stage of the disease.  It was assumed that the CT26-FL3 
would be metastatic by the end of the experiment; however, we did not want to assume 
any metastatic potential.  All of the day 8 (at sacrificing) draws have black lines around 
the data points, while all of the day 1 (pre-surgery) draws do not.  The information in this 
graph can be difficult to tell which groups should be grouped together.  Therefore, Figure 
3.11 will be used to clarify this. 
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Figure 3.11: PCA plot of day 1 (pre-surgery bleed) and day 8 (sacrificing bleed).  The boxes around CT26-FL3-8 
and CT26-8 represent that these two groups should be clustering together, while all of the unboxed samples 
should also be clustering together.  This ideally would create two populations. This is created with bright raw 
numbers. 
This is the same PCA plot from Figure 3.10, however boxes have been added to 
clarify the groupings that were expected.  Ideally, it was expected that there would be two 
populations.   
The first grouping would be all of the CT26-8 and CT26-FL3 8 (both of these are 
boxed in the legend) data points.  This grouping was expected because all of these mice 
would have had cancer, whether metastatic or not metastatic.  The second grouping 
would be the unboxed sample IDs in the legend.  This would include the control (day 1 
and 8), all of the sham (day 1 and 8), CT26 (day 1), and CT26-FL3 (day 1).  It was 
expected that the day 1 samples should all be grouped together because this was the pre-
bleed before any surgery and/or injection of cancerous cells occurred.  It was also 
-2 
-1.5 
-1 
-0.5 
0 
0.5 
1 
1.5 
2 
2.5 
-3 -2.5 -2 -1.5 -1 -0.5 0 0.5 1 1.5 2 
Control-1 Control-8 CT26-1 CT26-8 
CT26-FL3-1 CT26-FL3-8 Sham-1 Sham-8 
 79 
expected that the control and sham day 8 would stay with the day 1 (pre-bleed) samples 
because these mice had not any cancerous cell injection. 
While the majority of the points were grouped in the way hypothesized, there 
were two data points (both denoted with an arrow pointing to them)-CT26-FL3-8 and 
CT26-1 that seem to be outside of the trend that was expected.  As stated before, the 
numbers used for this analysis was using the raw bright numbers extracted from the 
MATLAB experiment.  At this time, the lab was attempting to figure out which numbers 
to use from the sensor array as the numbers given from MATLAB are given with 
different channels (red, green, blue, and bright).  With this in mind, bright normalized 
was run to look at the PCA plot given.  This plot is shown in Figure 3.12. 
 
Figure 3.12: PCA plot of day 1 (pre-surgery bleed) and day 8 (sacrificing bleed).  The boxes around CT26-FL3-8 
and CT26-8 represent that these two groups should be clustering together, while all of the unboxed samples 
should also be clustering together.  This ideally would create two populations.  This is created with normalized 
bright numbers. 
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The samples that were expected to group together are boxed as in the last plot and 
all other samples were expected to be together for the reasons stated above.  When using 
the normalized bright numbers, there is one point, denoted with an arrow, which is 
grouping in a place that was not expected.  This point, C26-FL3-8, should be a blood 
draw from a highly metastatic mouse at the sacrifice day, however, is grouping near the 
control mice from the last day. 
Upon first analysis of the data, it looked as though the SL array could distinguish 
between the non-cancerous draws and the cancerous draws, however, it was a very 
limited data set.  With this in mind, it was decided that it would make the most sense to 
choose one of the mid-experiment draws to look at the results in a similar way.  This 
would include the addition of day 4 (mid-way through the experiment), approximately 
twenty days into the experiment.  PCA is still being used because it is an unguided 
statistical method.  The plot below uses SL sensor array data that is the normalized bright 
numbers.  The plot is shown in Figure 3.13.   
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Figure 3.13: PCA plot of day 1 (pre-surgery bleed-points without outlines), day 4 (near midpoint of the 
experiment-points with dashed outlines), and day 8 (sacrificing bleed-points with black outline).  The boxes 
around CT26-FL3-8 and CT26-8 represent that these two groups should be clustering together. This is created 
with normalized bright numbers. 
The day 1 points (pre-surgery bleed) are the data points without the outlines.  The 
day 4 points (close to midway through the experiment) have the dashed lines around 
them, while the day 8 points (sacrifice bleed) are the points with the solid black line 
around them.  The assumption was still made that the CT26-FL3 day 8 and the CT26 day 
8 (both are boxed in the plot above) samples should group together.  It was also assumed 
that all of the pre-surgery points should group together (all points that are not outlined).  
These were the same assumptions made with the previous plots.  As can be seen in the 
plot above, the difficulty begins when adding in the day 4 points.  To simplify this 
process, the plot shown in Figure 3.13 is depicted again in Figure 3.14 with arrows drawn 
to the points that are in question. 
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Figure 3.14: PCA plot of day 1 (pre-surgery bleed-points without outlines), day 4 (near midpoint of the 
experiment-points with dashed outlines), and day 8 (sacrificing bleed-points with black outline).  The boxes 
around CT26-FL3-8 and CT26-8 represent that these two groups should be clustering together.  Arrows are 
drawn to the points that information is not known about where these points should cluster. This is created with 
normalized bright numbers. 
It can be inferred that the sham day 4 and control day 4 (green points with dashed 
lines as the outline), should cluster with all pre-surgery points as well as sham day 9 and 
control day 8.  The points that have arrows drawn to them are the points in question 
where they are grouping.  It can be seen that there are significantly more points that are in 
question that in Figure 3.12.   
The main disadvantage for the designed experiment is that there was no external 
validation of what stage each mouse was in.  For instance the CT26-4 point towards the 
right of the plot looks as if it is grouping with the points that would be without cancer 
(sham, control, and pre-surgery).  The problem is that it is not known whether this 
particular mouse had cancer at the time or if in fact the cells had not grown in the mouse.  
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The problem with the CT26-FL3 mice is that when the blood draws were taken it was 
unknown whether the cells had metastasized.  All samples from Day 1, 2, 4, 6, and 8 
were analyzed, however, the complications seen in the above graph were multiplied. 
3.9 CONCLUSIONS 
The intent of this experiment was to evaluate the SL array in terms of being able 
to distinguish between healthy, cancerous non-metastatic, and cancerous metastatic mice.  
This would have given detailed information about when the SL array could detect a 
change in metastatic potential.  All of the previous experiments with the SL array had 
been used on cell lines in which the metastatic potential was already established and not 
changing in vivo.   
The longitudinal mouse study done Part 2 of Chapter 3 indicated promise when 
comparing the pre-bleed experiments with those from the sacrificing bleed.  With the 
exception of one point, it appeared as though all of the points containing pre-bleed as 
well as the sacrificing bleed for the sham and control mice were a population, while the 
CT26 and CT26-FL3 day 8 mice were another population.  Difficulty began to arise 
when adding in additional days without a way to externally validate the cancer stage in 
the mice.  Five days were analyzed (Days 1, 2, 4, 6, 8), however the data did not appear 
to group in any way.  The additional days were not analyzed due to a cost-benefit 
analysis of the data that was being generated.  The following section will describe the 
future work to make this experiment valuable. 
3.10 FUTURE WORK 
While the initial Day 1 and Day 8 experiments showed promise, the primary 
problem to address in doing an additional longitudinal study is that of external validation.  
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In order to test the array’s sensitivity in detecting cancer and the metastatic changes, the 
experiment would need a way to look at where the cancerous tumor is and has this tumor 
metastasized.   
Dr. Marj. Peña’s has the CT26 and CT26-FL3 cells that contain a fluorescent tag.  
The Center for Colon Cancer Research (CCCR) at the University of South Carolina has 
the instruments necessary for imaging whole mouse specimens with anesthesia.  In an 
ideal experiment, each blood draw from a particular mouse would have a corresponding 
picture of that mouse which would depict the fluorescent cancerous cells.  This would 
allow for the researcher to be able to “quantify” the cancer and correlate this to the SL 
array’s response.  With this information, it would no longer be a question why a CT26-
FL3 mouse was clustering with a CT26 sample.  The picture could give information 
about if the cells had metastasized or not.  This information is invaluable in determining 
the efficacy of the SL array.  This future experiment could also include using an albumin 
removal kit that was effective in mouse samples.  In addition, a piece of the final tumor 
could be given to the investigator in order to look at the differences in the tumor response 
form the serum response.  Based on the proof-of-concept experiment in Chapter 2, it can 
be inferred that these responses would be different, however, it would be interesting to 
see in an in vivo experiment if this was true. 
3.11  EXPERIMENTAL FOR CT26-FL3 REVERSION STUDY (CHAPTER 3 PART 1) 
Cell Culture 
CT26-FL3 cell line used a media made up of Dulbecco’s Modified Eagle Medium 
(DMEM) purchased from VWR (45000-734), 10% FBS (50mL) purchased from VWR 
(45000-734) and 1% (5mL) antibiotics/antimycotics purchased from VWR (45000-616). 
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Media Preparation 
Remove 55mL of media from the bottle and place in a centrifuge tube.  You can 
use this later for starving cells if needed.  Add the FBS and antibiotics/antimycotics in 
with a pipette.  Do not pour this in.  After everything has been added to the media use a 
larger pipette and pipette up and down in order to thoroughly mix the media.  You can do 
this cold if you are not using the media for anything at this time. 
Thawing Stocks 
Typically, the initial thaw of a stock will want to be done in a T25 flask.  Once 
you know that cell viability is high for a cell stock, you can thaw into a T75 flask.  If you 
notice the T25 is confluent fast, the next time you can thaw into a T75.  Pre-warm your 
full media (all additives added) to 37˚C.  Make sure you have everything you need to 
thaw the cells in your hood ready to go, as DMSO is toxic to cells so they need to be 
thawed and thawed in a larger volume of media. 
Place about 5mL of warm media into a 15mL Falcon tube.  Pipette small amounts of 
warm media into the cryogenic vial.  You will need to pipette a small amount in and then 
pipette up and down.  As some of the cell stock thaws, place it into the falcon tube with 
the other warm media to dilute the DMSO.  Keep adding the warm media and removing 
the DMSO/cell solution to media until all of the stock has thawed.  The following day 
remove the media and add fresh media.  Be careful to not do this too soon after.  Dead 
cells and live cells look different yet they both float (dead cells will look like broken dark 
pieces where live unattached cells will look like nice healthy spheres).  Usually, cells 
were split 2-3 times before running any experiments to make sure these were healthy and 
viable.   
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Feeding the Cells 
Feeding the cells requires the pipetting of old media off before putting new media 
on.  I would suggest changing the media every couple of days when not splitting the cells.  
The pink media will begin to turn orange when the cells are either too confluent or the 
media needs to be changed (you should not let it get to this point).  The media should be 
warm (37˚C) for this step. 
Splitting Cells 
The trypsin/EDTA media should be warmed in incubator to 37˚C before 
beginning the process of splitting the cells.  The cells should be at 70-75% confluence 
prior to splitting.  Take the existing media off of the cells and put into the waste 
container.  The same pipette may be used as long as it does not touch the outside of the 
flask or any part of the hood.  Wash the back of the flask with 1-2 mL of the 
trypsin/EDTA solution then pipette this off and put into waste.  This will remove the dead 
cells and excess media that may not have come off with the first media removal.  Then 
(with a fresh pipette) add trypsin/EDTA to the flask.  The amount needed will depend on 
the flask size, but you want enough of the solution to cover the bottom of the flask when 
horizontal.  This will ensure that all cells will have the solution over them.  Place the 
flask back into the incubator (37˚C). 
The amount of time necessary to trypsinize the cells will depend on the cell line.  
In the beginning, check the cells every 1-2 minutes.  You can either hold the flask up to 
the light or look under the microscope to see if the cells are attached.  If you know that 
your cell line is hearty you can rub the back of the flask to speed up this process or in 
extreme cases hit the flask against your hand.  The cells should be floating when the have 
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completely detached.  Be mindful not to leave too many cells behind, as this will deplete 
your cell number. 
Wash the cells that have detached to the bottom of the flask with fresh warm 
media.  This amount will depend on the size flask used.  You may need to rinse the flask 
a couple of ties to ensure all of the cells have been removed.  Add this solution to a 15 
mL centrifuge tube and centrifuge for 4-5 minutes at 500 x g.  Be sure to not spin at too 
high of a rate as this will damage the cells.  Remove the supernatant and put in the waste 
container.  Add 1-2 mL of fresh media to the cell pellet.  Use a small pipette (p1000) and 
pipette this solution up and down.  This will ensure there are not clumps of cells when 
adding to a new flask.  Add the appropriate amount of microliters to each flask depending 
on the split you want and how many flasks you need.  If there are extra cells these can be 
placed in the waste container.  Add the media to the flask to make it to the total volume 
for each flask type (5 mL for T25, 10 mL for T75, and 20 mL for T125.  The following 
day check to make sure the cells have attached and there are not too many floating cells.  
You can change the media if you would like using warmed media. 
Making Stocks 
Only make stocks from cells that are actively growing and no more than 75-80% 
confluent.  If you are unsure, split the cells again and makes stocks from the next 
passage.  One T75 flask should result in 3-5 stocks, however, adjust this number 
depending on how many cells you want in your stock.  I tend to put more in so that it is a 
better chance of recovery.  Cell stocks are frozen in cryovials that can be found in the 
stockroom.  Label each vial with you initials, cell line, and cell passage. 
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Make sure everything is ready in the hood prior to these steps.  DMSO is toxic to 
cells so you must move quickly.  Have a cooled solution of 20% DMSO in FBS (this 
should have been filtered through a .2 µm filter.  Trypsinize the cells according to the 
instructions above, inactivate the trypsin with media, and put into a centrifuge tube.  
Centrifuge the cell suspension for 4-5 minutes at 500 x g and remove the supernatant.  
The following steps you will want to use a p1000 pipette.  Re-suspend the cell pellet in 
the usual full media.  Add the amount you will need to have is .5 mL * the number of 
stocks you are making.  Be sure to pipette the solution up and down in order to equally 
distribute the cells into all of the vials.  Add .5 mL of the cell suspension to each cryovial 
and then add .5 mL of the 20% DMSO-FBS solution. 
As soon as the DMSO is added the cells they must be frozen immediately.  The 
best way to do this is use the Mr. Frosty container and place in the freezer.  This will 
allow the temperature to reduce gradually.  The Mr. Frosty contains isopropanol that 
needs to be changed every five uses.  Mark the top of the container with a marker in order 
to indicate which use it was. 
Starving the Cells 
When the cells reached no more than 70% confluence, they were starved for 48 
hours.  The media did not include any supplements.  This was due to some cell lines 
dying when antibiotics were present.  For these first experiments, the maximum amount 
of media was used that one flask of cells could reasonably be split.  In most cases one T-
75 flask was split into five T-75 flasks.  One of these flasks would continue to grow 
further passages, while the four other flasks would be starved for the experiments.  In my 
notebook after the BCA it is seen that even with these flasks sizes, there was always more 
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protein that what was needed.  The only different to this set up was the first passage. 
CT26-FL3 +2 had less flasks because the initial cells given were in a petri dish rather 
than a full T-75 flask.  I have used as little as 5 mL of just media.  If you are doing an 
experiment where cells are being used in addition to the media the number of flasks 
needed is simply the number needed for cells.  
Concentration of Media for Secreted Proteins 
After 48 hours the media was removed from the flask and centrifuged to remove 
cell debris.  The media was pipetted off and put in a new tube.  The media was 
centrifuged in Amicon® 3K centrifuge tubes (EMD Millipore).  This will be the longest 
step in the process.  Only 10-15 mL will be spun through every twenty minutes.  Keep 
this in mind when deciding on how many flasks to use.  When the media is mostly spun 
through and there is only a small amount in the bottom of the filter (be sure not to let the 
filter go dry) it is a good idea to rinse PBS through in order to get rid of all of the media. 
If colored media is being used when the media is no longer colored and is a true clear you 
have finished the wash step.  If the media is colorless it will take a little more intuition to 
figure this out.  There should be a small amount of liquid in the filter tube (around 1500 
µL).  Pipette this out with a p200 pipette and tip (yellow).  Due to the filter size you want 
to make sure the pipette tip reaches the bottom because this is where the protein is.  After 
pipetting the solution out in a 15 mL centrifuge tube add PBS and rinse the filter pipetting 
up and down multiple times.  
Acetone Precipitation of Secreted Proteins from Media 
The protein is then precipitated with ice-cold acetone stored in the -30 degrees 
Celsius freezer.  Add four times the amount of acetone to the protein solution.  For 
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example, if there is 2 mL of protein 8 mL of acetone would be added.  Shake the tube in 
order to see a white fluffy precipitate.  At this point, the protein solution can be stored in 
the -30 degrees Celsius freezer overnight if you wish or for a minimum of an hour.  The 
following day (or after some time) take the sample out of the freezer, spin it down, and 
remove the acetone.  All the centrifuge tube to sit in the hood for 30 minutes to an hour to 
make sure the acetone is completely evaporated.  At this point, the protein can be treated 
like any other protein sample.  Usually (if moving on to the labeling step), the protein is 
re-suspended in carbonate buffer using only the amount necessary to completely dissolve 
(starting with about 1 mL each time).  This will depend on the amount of protein 
recovered.   
Membrane Proteins and Glycoproteins 
The cells were scraped off the flask using a cell scraper.  The flask was rinsed 
with PBS and the solution was centrifuged.  The PBS was taken off to leave behind a cell 
pellet.  This can be stored in the -30 degree Celsius freezer for a bit of time or in the -80 
degree Celsius freezer for an extended period of time.  The plasma glycoproteins and 
proteins were extracted using the Qiagen® Plasma Membrane Protein Kit.  The protein at 
the end is in elution buffer and must be spun into carbonate buffer purified using 
Amicon® 10K centrifuge (spin) tubes (EMD Millipore).  The solution was put into the 
spin tube and spun for about 8 minutes at 4000g.  The time spun may change depending 
on protein concentration, but you want to spin until it is at the “2” line on the tube.  When 
the solution is at the “2” line, 1.5 mL of carbonate buffer is put in the exchange tube and 
spun for 5 minutes.  Again it is checked to make sure the solution is at the “2” line.  At 
this point, you want to turn the small tube inside over and spin out into a micro centrifuge 
 91 
tube in a benchtop centrifuge.  Put in 300 µL of carbonate buffer and pipette up and 
down.  It is advantageous to use a yellow tip again for this step in order to get all the way 
down in the filter.  Turn tube over and spin again. Rinse tube with 2-100 µL increments 
of carbonate buffer. 
Labeling of Membrane and Secreted Proteins/Glycoproteins 
The membrane proteins/glycoproteins and secreted proteins were labeled 
separately with fluorescein isothicyanate (FITC) in DMF and carbonate buffer.  2.8 mg of 
FITC was dissolved in 100 µL of DMF.  10 µL of the FITC solution was put into 200 µL 
of protein.  The total volume of the solution was brought up to 600 µL by adding 400 µL 
of carbonate buffer.  The protein solution was tumbled for 1 hr at 37 degrees Celsius and 
purified using Amicon® 10K centrifuge (spin) tubes (EMD Millipore).  The solution was 
put into the spin tube and spun for about 8 minutes at 4000g.  The time spun may change 
depending on protein concentration, but you want to spin until it is at the “2” line on the 
tube.  When the solution is at the “2” line, 1.5 mL of PBS is put in the exchange tube and 
spun for 5 minutes.  Again it is checked to make sure the solution is at the “2” line.  At 
this point, you want to turn the small tube inside over and spin out into a micro centrifuge 
tube in a benchtop centrifuge.  Put in 300 µL of PBS and pipette up and down.  It is 
advantageous to use a yellow tip again for this step in order to get all the way down in the 
filter.  Turn tube over and spin again.  If secreted proteins are being used, repeat the rinse 
step since there is a large concentration of protein.  If membrane extracts are being used 
be aware that there is not as big of a concentration and thus maybe rinse with 2-100 µL 
increments of PBS.   After labeling a BCA assay was done to quantify the amount of 
protein. 
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BCA Assay 
Thermo Scientific BCA kit was purchased from VWR.   
Sample Preparation 
If using secreted protein sample you may need to dilute your samples and run 
these with the concentrated sample to ensure the concentration falls within the range of 
the assay. If this BCA assay is done before labeling, the samples will be in carbonate 
buffer, thus your standards should be made in carbonate buffer.  If this BCA is done after 
the labeling steps, the samples will be in PBS and thus your standards should be made in 
PBS. 
Standard Preparation 
There is a standard 2 mg/mL solution included with the kit.  Put 100 µL of this 
solution into a small plastic tube.  Put 50 µL of carbonate buffer in several other tubes.  
Then take 50 µL of the 2 mg/mL solution in the first tube.  Be sure to vortex this several 
times (This is the first 1:2 dilution).  Then take 50 µL of that solution and put it in the 
next tube.  Continue this process.  Make sure you also have a blank standard (either 
carbonate buffer or PBS depending on what step you are doing this). 
Reagent Preparation 
The directions instruct you to make the reagent to be made 50:1.  200 µL of 
reagent is required for each well so the amount of total reagent will need to be calculated 
(200 µL x # of wells).  This can be done in a 15 mL centrifuge tube. 
Well Preparation 
Make sure the standards/samples are done in triplicate.  Put 10 µL in each well of 
standards and samples.  Then put 200 µL of reagent in all of the wells.  Make sure to then 
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mix each well with a pipette tip.  The plate should then be placed in the oven for 30-45 
minutes at 37 degrees Celsius.  Periodically check your plate to see if the standards have 
changed.  The plate is then read on the plate reader at 562 nm.  Be sure not to leave your 
plate for a long period of time.  It should be noted that this assay is not an endpoint assay 
and will continue to develop. 
Synthesis of Synthetic Lectins 
SLs are attached to Tentagel beads.  The beads are weighed out and put in 10mL 
of DMF(dimethylformamide) for ten minutes in order to swell the beads.  Meanwhile, 
Fmoc-Met-OH(10eq) is activated with HBTU(10eq) for 10min in 5% N-
methylmorpholine in DMF.  The amino acid solution is added and tumbled for 1 hour.  
The solution is drained and the beads are washed with DMF, MeOH(methanol), DMF, 
MeOH.  After the last washing, a ninhydrin test is performed on one or two beads to see 
if the amino acid has coupled.  If coupled, the Fmoc group is removed using 10mL of 
20% piperidine in DMF.  That process is repeated manually until the amino acids are on 
or a peptide synthesizer can be used.  The SL is then N- terminally acetylated using 
10mL of CH2Cl2 containing 5% pyridine and 5% acetic anhydride. 
Removal of protecting group on DAB (diamino acid)  
Diamino acid (DAB) has an ivDde protecting group on it.  In order to put on the 
boronic acids, these must be removed.  The protecting group is removed by adding 10mL 
of 2% hydrazine monohydrate in DMF and tumbling for 1 hour. 
Addition of Phenyl Boronic Acids (PBA) 
2-formylphenyl boronic acid (8eq) is dissolved in 10% MeOH in DMF.  
Activated 3Å molecular sieves and the PBA solution are added to the beads and tumbled 
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overnight at 37 degrees Celsius.  Sodium borohydride (NaBH4) (8eq) is added and gas 
was released over 30 min.  The beads then tumble for 4 hours.  The beads are washed 
with DMF and MeOH and the sieves are removed.  The beads are then washed again. 
Removal of Acid Labile Groups 
In order to remove the acid labile groups the beads are tumbled with 10mL of 
95% trifluoroacetic acid(TFA), 2.5% water, and 2.5% triisopropylsilane for 1 hours.  
After tumbling, the solution is taken off and washed with DMF, MeOH twice.  The 
synthetic lectins can then be washed with PBS three times in order to cut down on PBS 
wash time done before incubation.  After washing with PBS it is important that the tubes 
of SLs be place in the refrigerator and not the -30 degrees Celsius freezer. 
MALDI Sample Preparation 
Phenyl Boronic Acid (PBA) Group Removal 
This step can be avoided if a small amount of beads are taken out before the 
boronic acids are added.  Once removed, the rest of the SL synthesis steps are followed 
on the small amount of beads.  However, if the boronic acids are still attached and a 
MALDI is needed to be run these groups will need to be removed. 
Remove PBA groups by add 100 mmol solution of H2O2 to the 1.5 mL centrifuge 
tube containing the beads.  Put this tube at 50 degrees Celsius for 1hour.  After the hour, 
wash the beads with dH2O three times.  Add 50 µL of a 40 mg/mL solution of Cyanogen 
Bromide (CNBr) made in .1M HCl.  Make sure all work with CNBr is done in the hood.  
Place this solution in the dark (usually your drawer) for 15-18 hours.  Evaporate this 
solution using the speed vacuum centrifuge.  There should be a small amount of white 
substance at the bottom of the centrifuge tube. 
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MS Sample 
 Dissolve the sample obtained from the previous section in 10 µL of .1% TFA in 
H2O.  In order to make the matrix, make a saturated solution of α-cyano-4-hyroxy 
cinnamic acid (CHCA) in 50:50 acetonitrile/.1 % TFA in H2O.  Add 1 µL of sample to 
the desired spot on the plate for MALDI.  Add 1 µL of matrix to the same spot.  Pipette 
the 2 µL of solution up and down a few times to get a good mix of matrix and sample.  
Let the plate dry and take obtain MALDI spectra. 
Incubation with Synthetic Lectins (SLs) 
 Each synthetic lectin is weighed into a centrifuge tube (2mg) for the binding 
study.  The beads were washed with PBS twice and PBS with 1% bovine serum albumin 
(BSA) for 15 minutes.  This solution was removed and 1mL of .0002 mg/mL (50 fold 
dilution of a .1 mg/mL solution) of a particular protein is put in the tube and allowed to 
incubate overnight at room temperature.  The solution was removed and then washed 
with PBS three times.  After the last wash, the beads are re-suspended in about 500 µL of 
PBS to make the exchange to the microscope slide easier.   
Imaging the Beads 
The beads are imaged with a fluorescence microscope, Leica MZ 16F, using a 
GFP filter set.  It is imperative that all of the SLs in each cell line (in this case SL 1-9) 
were imaged at the same exposure time.  In order to do this, place each slide under the 
microscope and find the brightest SL.  Once this is found for a particular sample, 
optimize this slide to have the largest green value without saturating the camera (no more 
than 190 to be safe, 255 is the absolute max).  This number can be found by circling a 
bead in Adobe Photoshop® and pulling up the histogram information. After finding the 
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appropriate exposure time, pictures can be taken with care that most beads are within the 
Region of Interest (ROI) and not touching one another, as these beads would be thrown 
out. 
Data Analysis 
After the pictures have been taken they must be converted into JPG or JPEG as the 
camera takes these pictures as TIFF files.  There are protocols written in the lab to do this 
on a MAC or PC.  After conversion into jpeg, the files can then be run through a code in 
MATLAB® written by Dr. Greytak and modified by Anna Veldkamp.  The code used for 
these experiments was image analysis anna.  There is a protocol written in the lab that 
walks a user through the necessary steps to run the code.  This code essentially picks out 
each bead and provides information about area, bright number, red number, green 
number, and blue number.  It also gives information about where this bead was located in 
the picture so that you can identify a number for each bead.  The data is processed in 
excel and outliers are removed (1.5 IQD) in order to get the array information for the SLs 
with each protein type.  At this point, the data can be put into varying statistical models, 
the most common seen in this chapter are linear discriminant analysis (LDA), principal 
component analysis (PCA), and machine learning which is an extension of linear 
discriminant analysis (LDA). 
3.12 EXPERIMENTAL FOR MOUSE SERUM STUDIES (CHAPTER 3 PART 2) 
Mouse Serum Specific Protocols for Protocol A (No albumin depletion kit) 
Sample Preparation 
There is a limited amount of sample preparation.  However, there are a few things 
to keep in mind when the samples are received.  It is possible that there are glass pieces 
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from the capillary tubes in the smaller tube so make sure this is removed.  Some of the 
samples may contain tissue parts or blood.  Centrifuge these and then only take the 
serum.  Label the tube accordingly.  Generally, there is about 50 µL of serum for each 
sample received. 
Carbonate Buffer 
There is a lot of protein present in a serum sample.  To reduce the dilutions 
needed for a BCA assays, less serum can be taken here.  It will also leave serum in case 
further experiments need to be done or if the SL experiment needs to be re-done.  Safely, 
15 µL can be taken (I have used as little as 5 µL).  Dilute serum to 600 µL of carbonate 
buffer in a micro centrifuge tube. 
BCA Assay 
Thermo Scientific BCA kit was purchased from VWR.   
Sample Preparation 
If using secreted protein sample you may need to dilute your samples and run 
these with the concentrated sample to ensure the concentration falls within the range of 
the assay. If this BCA assay is done before labeling, the samples will be in carbonate 
buffer, thus your standards should be made in carbonate buffer.  If this BCA is done after 
the labeling steps, the samples will be in PBS and thus your standards should be made in 
PBS. 
Standard Preparation 
There is a standard 2 mg/mL solution included with the kit.  Put 100 µL of this 
solution into a small plastic tube.  Put 50 µL of carbonate buffer in several other tubes.  
Then take 50 µL of the 2 mg/mL solution in the first tube.  Be sure to vortex this several 
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times (This is the first 1:2 dilution).  Then take 50 µL of that solution and put it in the 
next tube.  Continue this process.  Make sure you also have a blank standard (either 
carbonate buffer or PBS depending on what step you are doing this). 
Reagent Preparation 
 The directions instruct you to make the reagent to be made 50:1.  200 µL of 
reagent is required for each well so the amount of total reagent will need to be calculated 
(200 µL x # of wells).  This can be done in a 15 mL centrifuge tube. 
Well Preparation 
 Make sure the standards/samples are done in triplicate.  Put 10 µL in each well of 
standards and samples.  Then put 200 µL of reagent in all of the wells.  Make sure to then 
mix each well with a pipette tip.  The plate should then be placed in the oven for 30-45 
minutes at 37 degrees Celsius.  Periodically check your plate to see if the standards have 
changed.  The plate is then read on the plate reader at 562 nm.  Be sure not to leave your 
plate for a long period of time.  It should be noted that this assay is not an endpoint assay 
and will continue to develop. 
Labeling 
Depending on the concentration from the BCA assay, only label a portion of the 
sample in carbonate buffer. The serum was labeled with fluorescein isothicyanate (FITC) 
in DMF and carbonate buffer.  2.8 mg of FITC was dissolved in 100 µL of DMF.  10 µL 
of the FITC solution was put into 200 µL of protein.  The total volume of the solution 
was brought up to 600 µL by adding 400 µL of carbonate buffer.  The protein solution 
was tumbled for 1 hr at 37 degrees Celsius and purified using Amicon® 10K centrifuge 
(spin) tubes (EMD Millipore).  The solution was put into the spin tube and spun for about 
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8 minutes at 4000g.  The time spun may change depending on protein concentration, but 
you want to spin until it is at the “2” line on the tube.  When the solution is at the “2” 
line, 1.5 mL of PBS is put in the exchange tube and spun for 5 minutes.  Again it is 
checked to make sure the solution is at the “2” line.  At this point, you want to turn the 
small tube inside over and spin out into a micro centrifuge tube in a benchtop centrifuge.  
Put in 300 µL of PBS and pipette up and down.  It is advantageous to use a yellow tip 
again for this step in order to get all the way down in the filter.  Turn tube over and spin 
again.  If you are using secreted proteins you can repeat the rinse step since there is a 
large concentration of protein.  If you are using membrane extracts you would want to be 
aware that there is not as big of a concentration and thus maybe rinse with 2-100 µL 
increments of PBS.   After labeling a BCA assay was done to quantify the amount of 
protein.  
Incubation with Synthetic Lectins (SLs) 
Each synthetic lectin is weighed into a centrifuge tube (2mg) for the binding 
study.  The beads were washed with PBS twice and PBS with 1% bovine serum albumin 
(BSA) for 15 minutes.  This solution was removed and 1mL of .0002 mg/mL (50 fold 
dilution of a .1 mg/mL solution) of a particular protein is put in the tube and allowed to 
incubate overnight at room temperature.  The solution was removed and then washed 
with PBS three times.  After the last wash, the beads are re-suspended in about 500 µL of 
PBS to make the exchange to the microscope slide easier.  
Imaging the Beads 
The beads are imaged with a fluorescence microscope, Leica MZ 16F, using a 
GFP filter set.  It is imperative that all of the SLs in each cell line (in this case SL 1-9) 
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were imaged at the same exposure time.  In order to do this, place each slide under the 
microscope and find the brightest SL.  Once this is found for a particular sample, 
optimize this slide to have the largest green value without saturating the camera (no more 
than 190 to be safe, 255 is the absolute max).  This number can be found by circling a 
bead in Adobe Photoshop® and pulling up the histogram information. After finding the 
appropriate exposure time, pictures can be taken with care that most beads are within the 
Region of Interest (ROI) and not touching one another, as these beads would be thrown 
out. 
Data Analysis 
After the pictures have been taken, convert into JPG or JPEG as the camera takes 
these pictures as TIFF files.  There are protocols written in the lab to do this on a MAC or 
PC.  After conversion into jpeg, the files can then be run through a code in MATLAB® 
written by Dr. Greytak and modified by Anna Veldkamp.  The code used for these 
experiments was image analysis anna.  There is a protocol written in the lab that walks a 
user through the necessary steps to run the code.  This code essentially picks out each 
bead and provides information about area, bright number, red number, green number, and 
blue number.  It also gives information about where this bead was located in the picture 
so that you can identify a number for each bead.  The data is processed in excel and 
outliers are removed (1.5 IQD) in order to get the array information for the SLs with each 
protein type.  At this point, the data can be put into varying statistical models, the most 
common seen in this chapter are linear discriminant analysis (LDA), principal component 
analysis (PCA), and machine learning which is an extension of linear discriminant 
analysis (LDA).  
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Mouse Serum Specific Protocols for Protocol B (using albumin depletion kit) 
Sample Preparation 
There are a few things to keep in mind when the samples are received.  It is 
possible that there are glass pieces from the capillary tubes in the smaller tube so make 
sure this is removed.  Some of the samples may contain tissue parts or blood.  Centrifuge 
these and then only take the serum.  Label the tube accordingly.  Generally, there is about 
50 µL of serum for each sample received.   
Albumin Depletion Kit Protocol 
The kit used is the Pierce Albumin Kit (Product #45160) Take about 25 µL (or 
half of each sample if there is less than 25 µL) for the albumin depletion kit steps.  The 
excess will ensure that there is enough protein even though there will be some protein 
loss at each step.  The 25 µL of sample will get diluted with 75 µL of wash buffer from 
the kit.  If there is less than 25 µL still only dilute with 75 µL of wash buffer.  The 
protocol in the kit was followed exactly.  In the wash step the protocol was followed 
exactly.  In the last step four total washes were done.  The protocol calls for 4-5. 
Carbonate Buffer Exchange from Wash Buffer 
This protocol is much the same as in all other experiments.  After the albumin 
depletion was steps there is about 200-300 µL. All was taken to spin into carbonate 
buffer purified using Amicon® 10K centrifuge (spin) tubes (EMD Millipore).  The 
solution was put into the spin tube and spun for about 8 minutes at 4000g.  The time spun 
may change depending on protein concentration, but you want to spin until it is at the “2” 
line on the tube.  When the solution is at the “2” line, 1.5 mL of carbonate buffer is put in 
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the exchange tube and spun for 5 minutes.  Again it is checked to make sure the solution 
is at the “2” line.  At this point, you want to turn the small tube inside over and spin out 
into a micro centrifuge tube in a benchtop centrifuge.  Put in 300 µL of carbonate buffer 
and pipette up and down.  It is advantageous to use a yellow tip again for this step in 
order to get all the way down in the filter.  Turn tube over and spin again. Rinse tube with 
2-100 µL increments of carbonate buffer. 
BCA Assay 
Thermo Scientific BCA kit was purchased from VWR.   
Sample Preparation 
If using secreted protein sample you may need to dilute your samples and run 
these with the concentrated sample to ensure the concentration falls within the range of 
the assay. If this BCA assay is done before labeling, the samples will be in carbonate 
buffer, thus your standards should be made in carbonate buffer.  If this BCA is done after 
the labeling steps, the samples will be in PBS and thus your standards should be made in 
PBS. 
Standard Preparation 
There is a standard 2 mg/mL solution included with the kit.  Put 100 µL of this 
solution into a small plastic tube.  Put 50 µL of carbonate buffer in several other tubes.  
Then take 50 µL of the 2 mg/mL solution in the first tube.  Be sure to vortex this several 
times (This is the first 1:2 dilution).  Then take 50 µL of that solution and put it in the 
next tube.  Continue this process.  Make sure you also have a blank standard (either 
carbonate buffer or PBS depending on what step you are doing this). 
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Reagent Preparation 
The directions instruct you to make the reagent to be made 50:1.  200 µL of 
reagent is required for each well so the amount of total reagent will need to be calculated 
(200 µL x # of wells).  This can be done in a 15 mL centrifuge tube. 
Well Preparation 
Make sure the standards/samples are done in triplicate.  Put 10 µL in each well of 
standards and samples.  Then put 200 µL of reagent in all of the wells.  Make sure to then 
mix each well with a pipette tip.  The plate should then be placed in the oven for 30-45 
minutes at 37 degrees Celsius.  Periodically check your plate to see if the standards have 
changed.  The plate is then read on the plate reader at 562 nm.  Be sure not to leave your 
plate for a long period of time.  It should be noted that this assay is not an endpoint assay 
and will continue to develop. 
Labeling 
Depending on the concentration from the BCA assay, only label a portion of the 
sample in carbonate buffer. The serum was labeled with fluorescein isothicyanate (FITC) 
in DMF and carbonate buffer.  2.8 mg of FITC was dissolved in 100 µL of DMF.  10 µL 
of the FITC solution was put into 200 µL of protein.  The total volume of the solution 
was brought up to 600 µL by adding 400 µL of carbonate buffer.  The protein solution 
was tumbled for 1 hr at 37 degrees Celsius and purified using Amicon® 10K centrifuge 
(spin) tubes (EMD Millipore).  The solution was put into the spin tube and spun for about 
8 minutes at 4000g.  The time spun may change depending on protein concentration, but 
you want to spin until it is at the “2” line on the tube.  When the solution is at the “2” 
line, 1.5 mL of PBS is put in the exchange tube and spun for 5 minutes.  Again it is 
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checked to make sure the solution is at the “2” line.  At this point, you want to turn the 
small tube inside over and spin out into a micro centrifuge tube in a benchtop centrifuge.  
Put in 300 µL of PBS and pipette up and down.  It is advantageous to use a yellow tip 
again for this step in order to get all the way down in the filter.  Turn tube over and spin 
again.  If you are using secreted proteins you can repeat the rinse step since there is a 
large concentration of protein.  If you are using membrane extracts you would want to be 
aware that there is not as big of a concentration and thus maybe rinse with 2-100 µL 
increments of PBS.   After labeling a BCA assay was done to quantify the amount of 
protein.  
Incubation with Synthetic Lectins (SLs) 
Each synthetic lectin is weighed into a centrifuge tube (2mg) for the binding 
study.  The beads were washed with PBS twice and PBS with 1% bovine serum albumin 
(BSA) for 15 minutes.  This solution was removed and 1mL of .0002 mg/mL (50 fold 
dilution of a .1 mg/mL solution) of a particular protein is put in the tube and allowed to 
incubate overnight at room temperature.  The solution was removed and then washed 
with PBS three times.  After the last wash, the beads are re-suspended in about 500 µL of 
PBS to make the exchange to the microscope slide easier.   
Imaging the Beads 
The beads are imaged with a fluorescence microscope, Leica MZ 16F, using a 
GFP filter set.  It is imperative that all of the SLs in each cell line (in this case SL 1-9) 
were imaged at the same exposure time.  In order to do this, place each slide under the 
microscope and find the brightest SL.  Once this is found for a particular sample, 
optimize this slide to have the largest green value without saturating the camera (no more 
 105 
than 190 to be safe, 255 is the absolute max).  This number can be found by circling a 
bead in Adobe Photoshop® and pulling up the histogram information. After finding the 
appropriate exposure time, pictures can be taken with care that most beads are within the 
Region of Interest (ROI) and not touching one another, as these beads would be thrown 
out. 
Data Analysis 
After the pictures have been taken they must be converted into JPG or JPEG as the 
camera takes these pictures as TIFF files.  There are protocols written in the lab to do this 
on a MAC or PC.  After conversion into jpeg, the files can then be run through a code in 
MATLAB® written by Dr. Greytak and modified by Anna Veldkamp.  The code used for 
these experiments was image analysis anna.  There is a protocol written in the lab that 
walks a user through the necessary steps to run the code.  This code essentially picks out 
each bead and provides information about area, bright number, red number, green 
number, and blue number.  It also gives information about where this bead was located in 
the picture so that you can identify a number for each bead.  The data is processed in 
excel and outliers are removed (1.5 IQD) in order to get the array information for the SLs 
with each protein type.  At this point, the data can be put into varying statistical models, 
the most common seen in this chapter are linear discriminant analysis (LDA), principal 
component analysis (PCA), and machine learning which is an extension of linear 
discriminant analysis (LDA). 
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: CHAPTER 4
INVESTIGATING METASTATIC POTENTIAL USING STATISTICAL 
METHODS 
4.0 ABSTRACT 
Statistical methods are an important tool in many fields.  This chapter will discuss the use 
of statistical methods to gain insight into the biochemistry of the sensor array.  
Specifically, it will use linear discriminant analysis and the application of training and 
test models to look at the use of 3T3, a mouse fibroblast cell line, as a healthy control.  It 
will also discuss the use of reference beads in investigating the limitations and parameters 
of the fluorescence microscopy that is used in the synthetic lectin array experiments. 
4.1 INVESTIGATION INTO A HEALTHY CONTROL 
As mentioned in Chapter 1, the synthetic lectin sensor array was used to classify 
seven different cell lines by metastatic potential.  The seven cell lines used are again 
listed in Table 4.1.  Note that there are cell lines that are of mouse and human species.  
There is also a range of metastatic potentials. 
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Table 4.1: Cell lines discriminated with Synthetic Lectin array.  The associated metastatic potentials are listed as 
well as the secondary metastatic site when applicable. 
 
As can be seen from this table the healthy control used was NIH/3T3 (ATCC® 
CRL-1658™), which is a mouse fibroblast cell line52.  Previous linear discriminant 
analysis has depicted that the cell line data was bimodal, or in two clusters.  Figure 4.1 
depicts a linear discriminant analysis done with the cell lines listed above using 3T3/NIH 
as a control.42   
 
Figure 4.1: LDA array response with cell lines of varying metastatic potential.  This analysis was a three-class 
classification based on metastatic potential (i.e., healthy, cancerous non-metastatic (lowly metastatic), cancerous 
metastatic (highly metastatic).  
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Recall that LDA is a guided statistical method meaning that the computer 
program has the information regarding which metastatic potential each cell line falls into.  
The analysis done above in Figure 4.1 was a three-class classification indicating that each 
cell line would classify as one of three groups (healthy/normal, cancerous non-metastatic 
(lowly metastatic), and cancerous metastatic (highly metastatic).  It can be seen when 
looking at the 3T3 data points (black diamonds) that there is a bimodal quality to the 
data.   
Initially, there were a few different hypotheses for the data would appear this 
way.  The first had to do with the cell line and whether this data was from the same cell 
stock.  It was hypothesized that perhaps the cells being from two different stocks would 
cause the bimodal trend. It was also thought that perhaps this was due to variability 
between different researchers methodology.  In order to answer these questions a 
significant amount of work was done to look through old experiments and compile all of 
the necessary information as well as the images from the incubation of 3T3 with the 
sensor array. It should be mentioned that the fluorescent intensity data collected from the 
images represented in Figure 4.1 was collected manually using Adobe® Photoshop.  All 
of the data used in the lab now is found by running the images in MATLAB® through a 
program written by Dr. Andrew Greytak.  With this in mind, all of the previous images 
used for this data were run through the program in MATLAB®. 
There were additional cell lines added to the data set represented in Figure 4.1.  It 
was decided that additional healthy cell lines would be added as well as addition 
replicated of 3T3.  Other prostate and breast cell lines were added to give additional 
information to the statistical program.  With this in mind, another researcher had 3T3 data 
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that was added to this set-AAV 3T3.  This data set is represented as the green squares.  
Additionally, in order to put another healthy cell into this data set MCF 10A (ATCC® 
CRL-10317™) was added.  This is a human mammary gland tissue.53 PC-3 (ATCC® 
CRL-1435™), a cancerous metastatic prostate cell line was also added.   This cell line 
was derived from the bone, a metastatic site.54 MCF7 (ATCC® HTB-22™), a metastatic 
breast cell line derived from a pleura effusion.55 
Figure 4.2 depicts the LDA plot for a three-class analysis of the sensor array data 
from these cell lines. Recall that the three-class analysis is the three groupings of healthy, 
cancerous non-metastatic (lowly metastatic), and cancerous metastatic (highly 
metastatic).  The green data points represent the healthy cell line data, while yellow data 
points represent the cancerous non-metastatic cell line data.  The red data points represent 
the cancerous metastatic cell line data.  The N=433 for this analysis and the leave one-
out-classification accuracy was 78%.  At this point in the lab only SLs 1, 3, 4, and 5 and 
thus that is the sensor array data used in this plot. 
 
Figure 4.2: LDA plot of N=433 and the leave-one-out classification accuracy was 85%. 
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While the classification accuracy was relative high (78%), but lower than the 
analysis represented in Figure 4.1 (97%), this was not the focus of running the analysis.  
The goal of this analysis was to gain insight into the bimodal nature of the healthy cell 
lines.  It was discovered that the bimodal data for 3T3 was actually two biological 
replicates done by the same researcher.  The green triangles (SJ 3T3 Rep 1) and the green 
Xs (SJ 3T3 Rep 2) represent this data.  Originally, it was thought that two different 
researchers generated this data.  It was also discovered that the cell line data was from the 
same stock of 3T3.  This ruled out the two hypotheses discussed previously.  The 
additional 3T3 data added (AAV 3T3- represented by the green squares) also depicted 
some bimodal properties.  The additional healthy cell line added (MCF 10A) clustered 
near one group of the 3T3 data.  There was no literature precedent that explained the 3T3 
data trend. 
In order to further study the data set, training/test statistical analysis was performed using 
Statistica®.   This is an application of linear discriminant analysis.  This analysis involves 
having a portion of the data be a training set, i.e. a set of data that the computer knows 
information about, in our case which metastatic potential the cell line falls in.  This would 
be the guided part of the analysis.  The test set is a group of data that the computer 
program does not know to which group this belongs.  The part of the analysis is 
unguided.  These analyses can be done in a variety of different ways in varying the 
percentage of data that is the training and test set.  Previous training/test analysis done in 
the lab used half of the data to create a model and the other half was put in as the test set.  
For the analysis that will be discussed below, a more stringent analysis was done.  One 
cell line was removed, a model was created with the other cell lines (test set), and then 
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the cell line was reinserted to determine the classification accuracy.  This was done in 
two different cases: three-class and two-class.  Three-class is defined as healthy, 
cancerous non-metastatic (lowly metastatic), and cancerous metastatic (highly 
metastatic), while two-class is defined as healthy and cancerous.   
Figure 4.3 represents the results from the training and test analysis for all cell 
lines in Figure 4.2.   The blue colored bars are the three-class classification accuracies for 
the test set (one cell line), while the green colored bars are the two-class classification 
accuracies for the test set.  To better explain this analysis one cell line, CT26, will be 
explained in detail.  The training set for the CT26 analysis would be all cell lines besides 
CT26, while the test set is CT26.  When the model created was three-class (healthy, 
cancerous non-metastatic, and cancerous metastatic), CT26 had test classification 
accuracy between 80-85%.  When the model was recreated as a two-class classification 
(healthy and cancerous), this classification accuracy was between 95-100%. The analysis 
demonstrates that all classification accuracies improve from three-class to two-class.  
This result is often seen in the sensor array data.  It is common in the data for the sensor 
array to have more overlap between the cancerous non-metastatic and cancerous 
metastatic data.  As can be seen from this analysis 3T3 has a low classification accuracy.  
In referring to the data points in Figure 4.2 this was expected as the bimodal properties of 
3T3 group a potion of the data with the cancerous non-metastatic data points. 
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Figure 4.3: Training/Test analysis for all cell lines represented in Figure 4.2.  The training set was all cell lines 
except one, while the test set was that individual cell line.  The three-class classification accuracies are colored 
blue, while the two-class classification accuracies are colored green. 
To investigate how 3T3 affects the training/test analysis of the data another 
analysis was done for each cell line, however, this time 3T3 was left out of the training 
model.  Figure 4.4 depicts the classification accuracies for this analysis. MCF 10A was 
left out because without 3T3 in the analysis there would not be another healthy cell line 
to put in the model when testing MCF 10A.   
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Figure 4.4: Class Training/Test analysis for most of the cell lines represented in Figure 4.2.  The training set was 
all cell lines except one, while the test set was that individual cell line.  The three-class classification accuracies 
are colored blue, while the two-class classification accuracies are colored green.  3T3 was left out of this analysis 
to look at its affect on the data and MCF 10A was removed because there would not be another healthy cell line 
in the model if this was removed to test. 
It is interesting to note that all of the classification accuracies (except three-class 
PC3) increase when 3T3 is removed from the model.  Also all of the two-class 
classification accuracies are 100% for every cell line analyzed.   
Another researcher’s sensor array data from 3T3 was found and a training test analysis 
was done for this cell line with the cell lines included in Figure 4.2.  The test data was all 
of the cell lines while the test data was this researcher’s 3T3 data.   
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Figure 4.5: Training test plot of 3T3 with the cell lines.  As can be seen, the test data should overlap with the 
healthy data, however, it overlaps with the cancerous non-metastatic data points (yellow diamonds). 
Being that this data was from the sensor array’s interaction with 3T3, a normal 
cell line the green triangles with black borders should have grouped with the other 
healthy cell lines (green triangles), however it can be seen that the test data overlaps with 
the cancerous non-metastatic (yellow diamonds).  The classification accuracy for this 
analysis was 0%. 
3T3 is commonly used as a control for a variety of studies, however, with this 
information the lab decided to move in the direction of using a healthy human colon cell 
line, CCD-841-CoN.45   
4.2 MICROSCOPE STUDIES WITH FLUORESCENCE REFERENCE BEADS 
At a certain point in lab issues began to arise with the microscope bulb and fluorescent 
microscope.  For this reason, reference beads, FocalCheck™ Fluorescent Microspheres 
Kit, 15µm, were bought from Invitrogen™.  These were reference beads that were 
mounted on slides.  While the issues with the bulb and microscope were eventually 
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worked out, the reference beads were then used for a time study and bleaching study.  
The first study that will be discussed is the microscope time study.  The information 
given when the pictures are run through MATLAB® is luminosity values from 0 to 255.  
The data is given in terms of the four channels: red, green, blue, and bright.  Bright is a 
weighted average of the three other channels.  When imaging beads, the optimal 
experimental set-up is that for a particular analyte that all SLs (1-9) are run at the same 
time.  For instance, the exposure time for each image of each SL of CT26 is 500ms.  The 
problem that can occur is that one SL is significantly brighter or dimmer than another.  
Occasionally this would lead to different exposure times.  Recall that after 255 the 
camera is saturated.  The time study was done for the reference beads from 500ms to 5s.  
This study was done in order to determine if the luminosity at 1s was the value at 500ms 
doubled.  The result for this study is depicted in Figure 4.6. 
 
Figure 4.6: Time Study done with reference beads to investigate the change in luminosity with exposure time. 
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As can be seen by the plot in Figure 4.6, the correlation between exposure time and 
luminosity is linear, it is not a slope of 1.  In order to calculate the luminosity change with 
respect to time, the y-intercept has to be taken into account which would indicate that the 
amount of dye present would have to be known.  
A luminosity study was also conducted with the reference beads.  The intent of 
the study was to determine if the luminosity would stay constant.  The study was run 
from 0 minutes to 5 minutes.  The results are shown below in Figure 4.7. 
 
Figure 4.7: Luminosity study over 5 minutes elapsed.  The luminosity remains consistent at least over 5 minutes. 
4.3 CONCLUSIONS AND FUTURE DIRECTIONS 
Statistical analyses are powerful tools to understand the biochemistry behind the 
SL array response.  This chapter demonstrated the usefulness of linear discriminant 
analysis with a training/test component in investigating a healthy cell line control, 3T3.  It 
was determined that a healthy human colon cell line would most likely be the best option.  
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This chapter also discussed the use of reference beads to investigate the microscope.  
Being that chronologically most of this data occurred prior to the data collection in 
Chapter 2 and 3 there are a limited number of future directions.  A healthy colon cell 
lines, CCD-841-CON, was used in subsequent experiments.  While the microscope will 
always prove to be rate limiting in terms of data collection, current lab members are 
investigating the use of flow cytometry for use with the SL sensor array. 
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